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ABSTRACT 
 
The tumor microenvironment is composed of cellular and stromal components 
such as tumor cells, mesenchymal cells, immune cells, cancer associated fibroblasts 
and the supporting extracellular matrix.  The tumor microenvironment provides crucial 
support for growth and progression of tumor cells and affects tumor response to 
therapeutic interventions.  To better understand tumor biology and to develop effective 
cancer therapeutic agents it is important to develop preclinical platforms that can 
faithfully recapitulate the tumor microenvironment and the complex interaction between 
the tumor and its surrounding stromal elements.  Drug studies performed in vitro with 
conventional two-dimensional cancer cell line models do not optimally represent clinical 
drug response as they lack true tumor heterogeneity and are often performed in static 
culture conditions lacking stromal tumor components that significantly influence the 
metabolic activity and proliferation of cells.  Recent microfluidic approaches aim to 
overcome such obstacles with the use of cell lines derived in artificial three-dimensional 
supportive gels or micro-chambers.  However, absence of a true tumor 
microenvironment and full interstitial flow, leads to less than optimal evaluation of tumor 
response to drug treatment.  Here we report a continuous perfusion microfluidic device 
coupled with microscopy and image analysis for the assessment of drug effects on 
intact fresh tumor tissue.  We have demonstrated that fine needle aspirate biopsies 
obtained from patient-derived xenograft models of adenocarcinoma of the lung can 
successfully be analyzed for their response to ex vivo drug treatment within this biopsy 
 vii 
trapping microfluidic device, wherein a protein kinase C inhibitor, staurosporine, was 
used to assess tumor cell death as a proof of principle.  Lastly, we tested the model for 
its ability to demonstrate similar results found in clinic when using a Wee1 inhibitor on 
osteosarcoma and an epidermal growth factor receptor inhibitor, Erlotinib, and inhibitors 
of programmed death 1 receptor and programmed death ligand 1 on lung 
adenocarcinoma fine needle aspirate biopsies.  This approach has the potential to study 
tumor tissue within its intact microenvironment to better understand tumor response to 
drug treatments and eventually to choose the most effective drug and drug combination 
for individual patients in a cost effective and timely manner. 
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CHAPTER ONE: 
INTRODUCTION 
 
Note to Reader 
 Figures in this chapter have been previously published in Cancer Facts & Figures 
©2017, American Cancer Society, Inc., Surveillance Research and DevCan: Probability 
of Developing or Dying of Cancer Software, Version 6.7.4. Statistical Research and 
Applications Branch, National Cancer Institute, 2016.  The letter of permission to reprint 
is listed in Appendix A [1]. 
 
Chapter Synopsis 
Here in we discuss a brief overview of the current treatment options available to 
cancer patients and the potential drawbacks to those options.  Second, we will review 
the latest chemosensitivity testing models and their ability to pair patient cancer cells to 
therapies and measure the efficacy of each treatment option.  Also, we will explore the 
tumor microenvironment and how research has shown its impact on how the tumor 
specifically responds to treatment urging clinicians to tailor treatment to individual 
patients for a more personalized approach to cancer therapies.  Lastly, we will introduce 
an investigative platform that would allow for further detailed research on a patient’s 
individual tumor microenvironment and its interaction and response to cancer 
treatments.  The platform, a small scale and detailed approach of microfluidics, offers a 
working model that mimics dynamic properties similar to how the tumor experiences 
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forces and therefore is a better representation of in vivo like conditions unlike traditional 
two-dimensional platforms used routinely in research.  Our investigation will focus on 
targeted therapies such as Erlotinib and checkpoint inhibitors, MK-1775 and 
programmed death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) 
immunotherapy drugs and their effects on patient derived lung adenocarcinoma fine 
needle aspirate biopsy (FNAB) tumor samples.  
 
Current Standards in Cancer Care	
 The American Cancer Society reports that in 2017, there will be an estimated 
1,688,780 new cancer cases diagnosed and 600,920 cancer deaths in the Unites States  
(Figure 1) [1].  
 
 
Figure 1.  Leading sites of new cancer cases and deaths - 2017 estimates [1]. 
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Selected Cancers
This section provides basic information on risk factors, 
symptoms, early detection, and treatment, as well as 
statistics on incidence, mortality, and survival, for the 
most commonly diagnosed cancers and may have limited 
relevance to rare cancer subtypes. However, information 
on some rare subtypes can be found in the Special 
Section on page 30.
Breast
New cases: In 2017, invasive breast cancer will be 
diagnosed in about 252,710 women and 2,470 men in the 
US. An additional 63,410 new cases of in situ lesions of the 
breast will be diagnosed in women. Breast cancer is the 
most frequently diagnosed cancer in women (Figure 3).
Incidence trends: From 2004 to 2013, the most recent 10 
years for which data are available, invasive breast cancer 
incidence rates were stable in white women and increased 
by 0.5% per year in black women, a trend that has resulted 
in the convergence of rates in these two groups.
Deaths: An estimated 41,070 breast cancer deaths (40,610 
women, 460 men) will occur in 2017. Breast cancer is the 
second-leading cause of cancer death in women.
Mortality trends: The female breast cancer death rate 
declined by 38% from its peak in 1989 to 2014 due to 
improvements in early detection (through increased 
awareness and screening) and treatment, translating to 
297,300 fewer breast cancer deaths. In contrast to 
incidence, recent trends in the death rate were similar in 
white and black women, with a decline of about 1.8% per 
year from 2005 to 2014.
Signs and symptoms: The most common symptom of 
breast cancer is a lump or mass in the breast. Less 
common symptoms include other persistent changes to 
the breast, such as thickening, swelling, distortion, 
tenderness, skin irritation, redness, scaliness, and nipple 
abnormalities or spontaneous nipple discharge. 
Figure 3. Leading Sites of New Cancer Cases and Deaths – 2017 Estimates
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Estimates are rounded to the nearest 10, and cases exclude basal cell and squamous cell skin cancers and in situ carcinoma except urinary bladder. 
©2017, American Cancer Society, Inc., Surveillance Research
Lung & bronchus 84,590 27%
Colon & rectum 27,150 9%
Prostate 26,730 8%
Pancreas 22,300 7%
Liver & intrahepatic bile duct 19,610 6%
Leukemia 14,300 4%
Esophagus 12,720 4%
Urinary bladder 12,240 4%
Non-Hodgkin lymphoma 11,450 4%
Brain & other nervous system 9,620 3%
All sites   318,420 100%
Lung & bronchus 71,280 25%
Breast 40,610 14%
Colon & rectum 23,110 8%
Pancreas 20,790 7%
Ovary 14,080 5%
Uterine corpus 10,920 4%
Leukemia 10,200 4%
Liver & intrahepatic bile duct 9,310 3%
Non-Hodgkin lymphoma 8,690 3%
Brain & other nervous system 7,080 3%
All sites   282,500 100%
Prostate 161,360 19%
Lung & bronchus 116,990 14%
Colon & rectum 71,420 9%
Urinary bladder 60,490 7%
Melanoma of the skin 52,170 6%
Kidney & renal pelvis 40,610 5%
Non-Hodgkin lymphoma 40,080 5%
Leukemia 36,290 4%
Oral cavity & pharynx 35,720 4%
Liver & intrahepatic bile duct 29,200 3%
All sites    836,150 100%
Breast 252,710 30%
Lung & bronchus 105,510 12%
Colon & rectum 64,010 8%
Uterine corpus 61,380 7%
Thyroid  42,470 5%
Melanoma of the skin 34,940 4%
Non-Hodgkin lymphoma 32,160 4%
Leukemia 25,840 3%
Pancreas 25,700 3%
Kidney & renal pelvis 23,380 3%
All sites    852,630 100%
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Cancer remains the second most common cause of death in the U.S., accounting 
for nearly 1 of every 4 deaths [1].  In the US, approximately 41 out of 100 men and 38 
out of 100 women will develop cancer during their lifetime (Figure 2) [1]. 
 
 
Figure 2.  Probability (%) of developing invasive cancer during selected age intervals by sex, US, 2011-
2013 [1]. 
 
Cancer is a disease or group of diseases characterized by the uncontrolled 
division and spread of abnormal cells due to a failure of checks and balances that 
control cell numbers.  Cancer may be caused by external factors such as tobacco, 
infectious organisms, and an unhealthy diet, as well as internal factors, such as genetic 
mutations, hormones, and immune conditions.  Often these factors work in synergy to 
cause and exacerbate the disease.  A 2009 database included 291 genes implicated in 
cancer [2] and it is estimated that only 50% of these mutations are known [3]. 
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Leuk mia 
New cases: An estimated 54,270 new cases of leukemia are 
expected in 2015. Leukemia is a cancer of the bone marrow and 
blood and is classified into four main groups according to cell 
type and rate of growth: acute lymphocytic (ALL), chronic lym-
phocytic (CLL), acute myeloid (AML), and chronic myeloid 
(CML). The majority (91%) of leukemia cases are diagnosed in 
adults 20 years of age and older. Among adults, the most common 
types are CLL (36%) and AML (32%). In contrast, ALL is most 
common before age 20, accounting for 76% of cases. Overall leu-
kemia incidence rates have been slowly increasing over the past 
few decades; from 2007 to 2011, rates increased by 1.6% per year 
in males and 0.6% per year in females. 
Deaths: An estimated 24,450 deaths are expected to occur in 
2015. In contrast to incidence, death rates for leukemia have 
been declining for the past several decades; from 2007 to 2011, 
r tes d creased by about 1.0% per year in both sexes. 
Signs and symptoms: Symptoms may include fatigue, paleness, 
weight loss, repeate  infections, fever, bruising easily, and nose-
bleeds or other hemorrhages. In acute leukemia, these signs can 
appear suddenly. Chronic leukemia typically progresses slowly 
with few symptoms and is often diagnosed during routine blood 
tests. Patients with CML or CLL may experience pain or a sense 
of fullness in the upper left abdomen due to an enlarged spleen, 
while swollen lymph nodes can be seen in patients with CLL. 
Risk factors: Exposure to ionizing radiation increases the risk 
of most types of leukemia (excluding CLL). Medical radiation, 
such as that used in cancer treatment, is one of the most com-
mon sources of radiation exposure. Leukemia may also occur as 
a side effect of chemotherapy. Children with Down syndrome 
and certain other genetic abnormalities are at increased risk of 
leukemia. Workers in the rubber-manufacturing industry also 
have an increased risk. Studies suggest that obesity increases 
the risk of leukemia. 
Some risk factors are most clo ely associated with specific types 
of leukemia. For example, family history is a strong risk factor 
for CLL. Cigarette smoking is a risk factor for AML in adults, and 
there is accumulating evidence that parental smoking before 
and after childbirth may increase the risk of childhood leuke-
mia. Th re is limit d evidence that mater al exposure to paint 
fumes also increases the risk of childhood leukemia. Exposure 
to certain chemicals, such as formaldehyde and benzene (a com-
ponent in cigarette smoke and gasoline that has become more 
regulated due to its carcinogenicity), increases the risk of AML. 
Infection with human T-cell l u emia virus type I (HTLV-I) can 
cause a rare type of leukemia called adult T-cell leukemia/lym-
phoma. The prevalence of HTLV-I infection is geographically 
localized and is most common in southern Japan and the Carib-
bean; infected individuals in the US tend to be immigrants from 
endemic regions or their descendants. 
Probability (%) of Developing Invasive Cancer during Selected Age Intervals by Sex, US, 2009-2011*
Birth to 49 50 to 59 60 to 69 70 and Older Birth to Death
All sites† Male 3.4 (1 in 29) 6.7 (1 in 15) 15.1 (1 in 7) 36.0 (1 in 3) 43.3 (1 in 2)
Female 5.4 (1 in 19) 6.0 (1 in 17) 10.0 (1 in 10) 26.4 (1 in 4) 37.8 (1 in 3)
Breast Female 1.9 (1 in 53) 2.3 (1 in 44) 3.5 (1 in 29) 6.7 (1 in 15) 12.3 (1 in 8)
Colon & rectum Male 0.3 (1 in 300) 0.7 (1 in 148) 1.3 (1 in 80) 3.9 (1 in 26) 4.8 (1 in 21)
Female 0.3 (1 in 326) 0.5 (1 in 193) 0.9 (1 in 112) 3.5 (1 in 28) 4.5 (1 in 22)
Kidney & renal pelvis Male 0.2 (1 in 468) 0.3 (1 in 292) 0.6 (1 in 157) 1.3 (1 in 76) 2.0 (1 in 49)
Female 0.1 (1 in 752) 0.2 (1 in 586) 0.3 (1 in 321) 0.7 (1 in 134) 1.2 (1 in 84)
Leukemia Male 0.2 (1 in 419) 0.2 (1 in 598) 0.4 (1 in 271) 1.3 (1 in 75) 1.7 (1 in 59)
Female 0.2 (1 in 516) 0.1 (1 in 968) 0.2 (1 in 464) 0.9 (1 in 117) 1.2 (1 in 84)
Lung & bronchus Male 0.2 (1 in 578) 0.7 (1 in 140) 2.0 (1 in 49) 6.6 (1 in 15) 7.4 (1 in 13)
Female 0.2 (1 in 541) 0.6 (1 in 173) 1.6 (1 in 64) 4.9 (1 in 20) 6.2 (1 in 16)
Melanoma of the skin‡ Male 0.3 (1 in 294) 0.4 (1 in 240) 0.8 (1 in 129) 2.1 (1 in 47) 3.0 (1 in 34)
Female 0.5 (1 in 207) 0.3 (1 in 323) 0.4 (1 in 246) 0.9 (1 in 112) 1.9 (1 in 53)
Non-Hodgkin lymphoma Male 0.3 (1 in 366) 0.3 (1 in 347) 0.6 (1 in 173) 1.8 (1 in 55) 2.4 (1 in 42)
Female 0.2 (1 in 543) 0.2 (1 in 483) 0.4 (1 in 233) 1.4 (1 in 72) 1.9 (1 in 52)
Prostate Male 0.3 (1 in 304) 2.3 (1 in 44) 6.3 (1 in 16) 10.9 (1 in 9) 15.0 (1 in 7)
Uterine cervix Female 0.3 (1 in 358) 0.1 (1 in 840) 0.1 (1 in 842) 0.2 (1 in 565) 0.6 (1 in 154)
Uterine corpus Female 0.3 (1 in 367) 0.6 (1 in 170) 0.9 (1 in 109) 1.3 (1 in 76) 2.7 (1 in 37)
*For those who are free of cancer at the beginning of each age interval. †All sites excludes basal cell and squamous cell skin cancers and in situ cancers except urinary 
bladder. ‡Statistic is for whites. 
Source: DevCan: Probability of Developing or Dying of Cancer Software, Version 6.7.1. Statistical Research and Applications Branch, National Cancer Institute, 2014. 
srab.cancer.gov/devcan.
Please note: The probability of developing cancer for additional sites, as well as the probability of cancer death, can be found in Supplemental Data at cancer.org/research/
cancerfactsstatistics/index.
American Cancer Society, Inc., Surveillance Research, 2015
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Cancer treatments include surgery, radiation, chemotherapy, hormone therapy, 
immune therapy, and targeted therapy.  Current treatment options are based on 
archived databases of patient records and their annotated responses to drug treatments 
during clinical trials.  Primary guidelines from clinical trials don’t account for patient 
diversity.  Rather, such trials include large statistical population samplings of patients, 
which lack personalized therapeutic approaches for individual cancer patients.  
Treatment response varies widely among patients and does not factor in patient specific 
mutations, which can interfere with pharmacodynamic response, nor disease 
heterogeneity at pathological, cellular and molecular levels.  The complexity increases 
further as clinicians try to resolve these differences while prescribing treatment plans for 
each patient and their individualized disease.  Therefore, treating large unselected 
groups of patients with the same treatment based on the histology alone is unlikely to 
improve outcomes.  These empirical approaches in cancer treatment result in many 
patients receiving multiple cycles of therapy without success before the lack of efficacy 
is identified. 
In the past few years, we have seen improvements in patient outcomes resulting 
from deployment of targeted agents in subtypes of lung cancers with activating 
mutations in genes such as receptor tyrosine kinases.  However, even patients with 
activating oncogene mutations typically have limited responses to targeted agents due 
to activation of compensatory pathways that mediate innate drug resistance to these 
targeted agents.  Epigenetics is a mechanism for switching genes on and off.  Errors in 
silencing genes for tumor suppression and DNA repair in addition to the activation of 
oncogenes by altered CpG island methylation patterns, histone modifications, and 
 5 
dysregulation of DNA binding proteins; further complicate the predictability of patient 
response to treatment.  There are epigenetic changes found in more than 70% of 
stomach and esophageal cancers and 60% of glioblastomas.  On average, a particular 
cancer drug is ineffective for 75% of patients [4].  There are many reasons why patients 
have varying response levels to treatment and also why one patient may suffer more 
adverse side effects than another.  Varying individual responses to drug treatments 
include pharmacokinetic events such as dosing, drug interactions, allergies and to a 
larger extent, their genetic predisposition.  There is also a high cost associated with 
ineffective treatments.  On average, a patient’s cost of treatment is $171,000 per year 
[5].  Importantly, the effects of failed courses of treatment are further devastating 
because they preclude patients from participation in clinical trials as a later option.  
Therefore, with limited reliability of biomarkers to determine efficacy of targeted drugs, 
there is a need for methods to predict response. 
The development of clinically relevant assays to predict and assess drug efficacy 
within a 24-48 hour pretreatment window would allow the identification of patients who 
may benefit from a certain therapy while sparing others from the side effects of toxic 
futile treatment.  Hence, clinically relevant and reliable drug testing approaches would 
effectively match the patient to the best therapy in the shortest possible time.  Thus, 
next generation treatments must clearly focus on patient specific responses to spare 
uncertain toxicity and additional non-effective prolonged courses of chemotherapy. 
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Current Chemosensitivity Testing Models 
Cell-based assays and preclinical animal models have provided researchers 
platforms to discover both molecular and genetic biomarkers related to the progression 
of the disease.  Current in vitro chemosensitivity testing models, using cell lines or 
cloned cells selected from patient tumors, do not represent the tumor heterogeneity and 
the true microenvironment of the tumor.  One of the main challenges in the development 
of in vitro assays to predict tumor response to treatment is availability of fresh tumor 
tissue obtained from patients.  In this context, biopsy samples are obtained by tumor 
FNAB, a minimally invasive established diagnostic procedure.  This procedure allows 
acquisition of enriched tumor cell populations to perform analytic molecular tests.  
Furthermore, an FNAB needle can be directed to different areas of a neoplasm and 
obtain a representative sample of a heterogeneous tumor while avoiding necrotic areas 
under ultrasound image guidance to provide viable tumor cells. 
More importantly, the cell culture conditions found in a conventional cell culture 
model may not be homogenous, primarily because of static and concentrated chemical 
gradients within the cell culture system.  Chemosensitivity assays that use primary 
cultures of cells grown from surgically excised tumor specimens and incubated with a 
panel of therapeutic drugs are also performed in static conditions, often in a well-plate 
configuration [6, 7].  Limiting the tumor samples to a static environment hampers full 
nutritive support confounding the true efficacy of the drug treatment.  Further, most 
biopsy driven models offer only an endpoint analysis of how the cancer cells respond to 
treatment without regard to each sample’s own baseline health prior to the initiation of 
the drug exposure [8].  The resulting poorly defined extracellular conditions in a cell 
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culture system can hamper precise quantification of the link between cellular responses 
and the tested conditions [9].  Although chemosensitivity testing is an intuitively 
attractive concept, to date they have failed to demonstrate clinical efficacy to predict 
tumor responses in vivo, mainly because the ex vivo growth of tumor cells in static well 
plate conditions may lead to artificial selection of specific tumor subpopulations 
depending on culture conditions, thereby limiting ultimate clinical correlation [10, 11]. 
 
The Tumor Microenvironment 
Elements of the tumor microenvironment have been shown to be instructive to 
tumor cells, making them more or less tumorigenic [12].  Genetic and epigenetic 
differences within each cell determine whether specific drug therapies will prove 
efficacious to each patient [13-15].  Tumor heterogeneity has proven culpable to the 
variability in response to chemotherapy.  The spatial architecture and the resulting 
distribution of cells within the tumor can affect how they interact with each other and 
their microenvironment, impacting proliferation, differentiation, morphology and a range 
of cellular functions [16, 17].  It has been demonstrated that the proliferation rate of the 
cells in a two-dimensional cell culture model are 110–158% higher than that of a three-
dimensional cell culture format [18, 19].  Therefore, cancer cells grown in three-
dimensional environments often show more resistance to cytotoxic agents than those 
grown in two-dimensional cultures [18].  Also, it is known that specific cancer drugs are 
more effective during the proliferative state [20].  Furthermore, within the tumor 
microenvironment additional complexity resides such as stromal elements that can 
promote or retard tumor growth.  Cancer does not exist in isolation but rather intimately 
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interacts with non-neoplastic host cells [21] and therefore such interactions should not 
be taken for granted and must be part of the investigation for drug efficacy.  Neoplasms 
are surrounded by dense fibrous or desmoplastic stroma, which itself contains 
proliferating fibroblasts, small endothelial-lined vessels, inflammatory cells, and other 
components [22].  The tumor and stroma interplay in a reciprocal fashion with tumor 
cells inducing the surrounding stroma with growth factors and their receptors countered 
by the stroma influencing differentiation of the tumor cells. 
 
Use of Microfluidics for In Vitro Assays 
A tumor is heterogenic receiving continued stimuli from its microenvironment 
where the cancer cells dynamically shift their response to both chemical 
communications and mechanical forces in time and space.  Therefore, to accurately 
assess a tumor’s response to drug therapy, the microenvironment’s response requires a 
dynamic but controlled and measured approach for multiple cell types over a consortium 
of time and conditions [23, 24].  Through the use of microfluidics, cultured environments 
can be controlled to homogeneous microenvironments with low chemical gradients [25-
27].  Unlike a static cell culture, a perfusion cell culture model can provide a system for 
continuous nutrient supply and removal of metabolic products, thereby maintaining a 
more stable culture environment [9, 28].  Additionally, a controlled environment offers 
the advantage of being capable of creating hydrodynamic forces, such as shear stress, 
in the physiological range as seen in vascular capillaries and tissues known to have 
Reynolds numbers <100, resulting in predominantly diffusion based characteristics, over 
spatial distances of approximately 200 µm [29, 30] within which cellular metabolite 
 9 
uptake, gaseous exchange and waste removal occurs [31].  Instances where Reynolds 
numbers are > 2000 [32] for fluid moving in a circular channel and Re>10 for flow with a 
circular object in a fluid, the fluid flow becomes turbulent.  Turbulence can then create 
disturbances and higher shear forces creating fluid stresses on cells and or tissues 
within the microfluidic device creating cellular and or tissue destruction.  Secondly, 
tissues that are greater than 200 µm thick may rely on additional advective fluid forces 
for where diffusion is limited.  Microfluidics can supply such advective forces through 
active perfusion of media delivering nutrients and metabolites at flow rates that are 
calculated to have shear forces within the physiological range.  Microfluidics are low 
cost, micro-sized footprints that offer high sensitivity with high throughput results while 
having the advantage of temporal control of physics, biology, chemistry and physiology 
at the cellular level [33].  Small dimensions, low burden on reagent use with controllable 
and well-defined culture conditions make microfluidics valuable for drug testing studies. 
 Recent in vitro microfluidic approaches have attempted to recapitulate some of 
the tumor architecture but relied mainly on cancer cell lines that lack important 
phenotypes of the primary cancer cells due to prolonged culture in serum with growth 
and attachment on tissue culture plastic; not representative of the parent tumor.  Three-
dimensional gels derived from animals such as bovine collagen are variable in 
composition [34, 35] and can pose variability between samples grown in their presence.  
Synthetic hydrogels often require post processing with radiation, ultraviolet, or chemical 
catalysts which may be toxic to the cells [35, 36].  Also, artificial three-dimensional 
scaffolds, contain less of the essential stromal elements such as extracellular matrix 
(ECM) components and stromal cells found in the tumor microenvironment in vivo and 
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therefore do not support an environment for native cellular behavior.  The interaction 
between cells and the ECM is intimate and dynamic.  The ECM applies mechanical 
forces that guide cellular organization [37] and directs cellular behavior and 
differentiation through inherent signaling proteins and or its diffusion properties of 
external and intercellular signaling [38].  Cells also can respond to their local 
environment, remodeling local ECM, by degrading or synthesizing new ECM elements 
[39].  Additionally, the diffusion of nutrients, metabolic products and soluble cytokines is 
critically controlled in tumors, which are difficult to mimic, by the artificial three-
dimensional matrix materials.  For example there is no distinct microporous structure in 
hydrogels thus, mass transport mainly depends on slow diffusion through submicron-
sized pores.  The density of the gels can cause variations in mass transport of oxygen 
and nutrients throughout the sample [40] and may influence the hydrodynamic 
properties of the microfluidic channel creating increased resistance to flow by occluding 
a greater percentage of the channel.  Variations in the microenvironment of the cellular 
samples and fluidic properties of the device further complicate analysis of drug effects 
on platform.  Still, the high water content (95.0–99.5%) enables sufficient exchange of 
essential biomolecules and metabolic end-products to maintain cell viability in a limited 
thickness but at the same time offers weak mechanical properties [41].  Static or 
diffusion-based fluidic models are provided by reservoirs on or off chip or with the 
fabrication of microchambers or cavities for the cell structures and nutritive media 
supply [42].  Other microfluidic systems deliver pulsatile flow with periods of flow and no 
flow or pulsations intermittently for purposes of nutritional and or drug delivery therefore 
delivering pressures and shear at varying levels [8, 43].  Fluid shear stress has 
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important consequences on the proliferation dynamics of cancer cells [44-46].  Applied 
shear resulting in the deformation of the cell membrane, leading to changes in signaling 
cascades, affects not only the cytoskeleton but also gene transcription that ultimately 
affects cell growth, survival and response to therapeutic agents. 
 One of the main challenges in the development of in vitro assays to predict tumor 
response to treatment is the availability of fresh tumor tissue obtained from patients.  
We have previously described a novel short-term ex vivo assay to explore 
pharmacodynamic predictors and indicators of response to anticancer drugs by using 
tumor fine needle aspiration biopsy (FNAB) samples.  The patient-derived pre-clinical 
xenograft mouse studies and the results of the clinical studies performed by our group 
demonstrated that the short term ex vivo assay has a high negative predictive value and 
provides pharmacodynamic data to identify patients whose tumor would likely respond 
to treatment [47].  To add to this ex vivo approach we have developed a novel three-
dimensional microfluidics approach using patient tumor samples obtained by FNAB that 
provide micron-scale tumor tissue where the interaction between tumor and its 
microenvironment are maintained in their biological configuration.  The device was 
fabricated from polydimethylsiloxane (PDMS) by a photolithography process having 10 
channels each with a centralized array of oblong posts that trap the biopsy when 
delivered into the device by injection.  The biopsy sample is held in place while the 
device is primed with fresh media.  Opportunistically, by design over static models, 
necrotic cellular debris and red blood cells resulting from the biopsy procedure can be 
flushed from the system before onset of experiment preventing background noise during 
sensitive detection modes of viability assessment.  The device is high-throughput in 
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which each channel may be fed by a separate reservoir or multiple reservoirs allowing 
single agent or combinatorial treatment regimens that have the capability to be also 
temporally altered throughout the progression of treatment.  FNAB tumor samples are 
added to the system and analyzed for their baseline health prior to the onset of 
treatment.  The FNAB tumor samples are then monitored throughout the treatment 
period for progression of death through apoptosis and viability signified by detection of 
esterase activity within the intact cell and phosphatidylserine proteins by antibody 
conjugation. 
We hypothesize that a re-circulating, multi-trap, multi-channel microfluidic device 
capable of introducing multiple drug combinations to patient derived biopsies will 
maintain the microenvironment of the tumor and may recapitulate more of an in vivo 
tumor response to drug treatment, which ultimately can be used as a tool for 
advisement for personalized cancer therapy.  Table 1 outlines the basic parameters 
from which two chemosensitivity assays operate in the clinic and how the proposed 
microfluidic device compares.  The microfluidic tumor trap device proposed operates 
within parameters that are more “in vivo like” and maintains the tumor architecture and 
microenvironment; including for the stromal components, fresh from the patient and or 
mouse model.  The FNAB sample is not prepped nor cells isolated and cloned from the 
samples.  Also, the FNAB samples are kept in biological shear force conditions that 
most mimic tumor in situ in the body while receiving full nutritive support.  The FNAB 
samples are continuously monitored in real-time for cellular viability in response to the 
device conditions and or drug insult without offline analysis and disrupting the testing 
environment.  Herein, we demonstrate a cytotoxic drug model using a known protein 
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kinase C (PKC) inhibitor staurosporine (SSP) [48] to optimize the microfluidic device 
towards a potential clinically relevant chemosensitivity assay.  We also tested the 
device with targeted drug Erlotinib to EGFR wild type and KRAS c.34G>T (G12C) 
resistant models, checkpoint inhibitor MK-1775; a Wee-1 inhibitor, in combination with 
gemcitabine on osteosarcoma models and anti-PD-1 and anti-PD-L1 
immunomodulatory checkpoint inhibitors on PD-L1 positive lung adenocarcinoma 
models and angiosarcoma models.  FNAB samples were taken from patient-derived 
xenograft mouse models for all significantly reported data although experiments were 
performed on patient direct samples for capability testing in the past. 
 
Table 1.  Comparison Chart of the Current Art of Chemosensitivity Assays and the 
Tumor Trap Device. 
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Conclusion 
The plethora of targeted agents suggests an endless number of potential 
combinations for cancer therapy and to overcome innate drug resistance that cannot be 
adequately evaluated in clinical trials.  There is a need for a cost-effective method for 
predicting the response of an individual patient’s tumor to a given therapeutic agent.  
Development of novel technologies, which permit short-term culturing of patient-derived 
tumor samples in a system suitable for high-throughput screening of cancer sensitivity 
to potential drugs or drug combinations may facilitate personalized cancer medicine and 
drug development efforts.  Thus, next generation treatments must clearly focus on 
patient specific responses to spare uncertain toxicity and additional non-effective 
prolonged courses of chemotherapy. 
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CHAPTER TWO: 
MICROFLUIDIC BIOPSY TRAPPING DEVICE 
 
Note to Reader 
 Portions of this chapter have been previously published in PLOS, 2017, 12(1):  
0169797 [49], and have been reproduced with permission from Public Library of 
Science.  PLOS is an open access journal and the legal disclaimer to reprint is listed in 
Appendix A.  The publication is listed in Appendix C. 
The device, Microfluidic Biopsy Trapping Device; herein described, is covered by 
two patent applications by the US Patent Office and listed in Appendix B one of which 
was accepted in 2017.  The U.S. Patent Office is a government owned agency and has 
open access to their patent. 
• 20150118742 Apparatus for Ex Vivo Microfluidic Analysis of Biologic 
Samples, published 04-30-2015 [50]. 
• 20140127733 Ex Vivo Microfluidic Analysis of Biologic Samples, published 
05-08-2014 [51]. 
Portions of this chapter refer to parallel microfluidic work performed during thesis 
work, Membrane-Integrated Microfluidic Device for High-Resolution Live Cell Imaging, 
and has been previously published in Biomicrofluidics, 2011, 5(4): 046501-046501-6, 
and has been reproduced with permission from AIP Publishing LLC [52].  The letter of 
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permission to reprint is listed in Appendix A.  The publication is listed in Appendix C.  
This work also resulted in a patent application listed in Appendix B. 
• 20120182609  Membrane-integrated Microfluidic Device For Imaging 
Cells, published 07-19-2012 [53]. 
Portions of this chapter refer to parallel microfluidic work performed during thesis 
work, Microfluidic Device for Trapping and Measuring Dielectric Properties of Multicell- 
Spheroids.  Work was published in Biomicrofluidics, 2011, 5(4): 046501-046501-6, and 
has been reproduced with permission from AIP Publishing LLC [54].  The letter for 
permission to reprint is listed in Appendix A.  The publication is listed in Appendix C.  
 
Chapter Synopsis 
 The chapter herein describes the design and development of the ”Microfluidic 
Biopsy Trapping Device for the Real-time Monitoring of the Tumor Microenvironment”, 
as we will refer to as the “Tumor Trap Device” in later sections.  The goal of this 
research was to development a platform system that can better assist clinicians and 
researchers for their drive to find better drug selection for their patients offering a 
personalized approach and an up-close snapshot and insight as to how the drug 
interacts on a cellular level with patient and or patient derived xenograft (PDX) tumor 
models.  In this chapter we will describe the specifications needed and tested to meet 
the requirements of the device for its intended goal.  Secondly, we will describe the 
design and fabrication process and the software tool, COMSOL Multiphysics that was 
used to predict how the device specifications would perform.  We will then summarize 
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the results of our validation testing of the software model to compare the accuracy of 
the tool for later prediction models of FNAB samples in device. 
 
Microfluidic Device Design and Fabrication 
The purpose and the goal of this research was to design and development a 
microfluidic device that would have the usability and features to successfully intake 
FNAB samples taken from fresh tumor either from patient or PDX models, of a few 
hundred micron size, and sustain their viability within device long enough to discriminate 
the efficacy of various chemotherapies on chip.  The tumor trap device was designed to 
allow for constant perfusion of fluids and for the delivery of nutrients and or drug to each 
FNAB sample.  The rate and volume of the fluid delivery would have to be at a shear 
force that would not alter the tumor tissue and allow for full fluid perfusion through the 
entire FNAB sample for full nutritive supply and or drug.  The device was deigned to be 
on the micron scale to offer minimal use of reagents.  The channel was designed to 
have an interior trap structure made of a series of seven oblong posts formed into a “V” 
shape (Figure 3B).  The “V” shape trap maintains the FNAB sample in channel within 
device while fluid flow is maintained.  The posts are oblong in shape with an aspect ratio 
of 2:1 so that the posts may retain their integrity as a three-dimensional structure and 
not easily damaged or ripped during the fabrication process.  The spacing between the 
posts is 25um sidewall to sidewall and 65um end to end so that tumor tissue may not 
escape during fluid flow as the cells are elastic and may deform to the shape of the 
containing trap structure through the spacing of the posts.  Also, the spacing between 
posts had to be large enough so that fluid flow would not be restricted (Figure 3A).  The 
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device herein tested, had 10 channels, however, the device can and has been made to 
include 15 or more channels depending the desired footprint and microscope stage 
parameters that the device rests during microscopy analysis.  Each channel is singularly 
perfused.  The channels may all be joined to a single reservoir or each channel to a 
separate reservoir so that each sample can remain discreet from the rest of the samples 
tested in the system.  The material used to fabricate the device was 
polydimethylsiloxane (PDMS), a silicon-based organic polymer.  PDMS was chosen due 
to its inert, non-toxic properties.  PDMS is low cost, thermally stable, and used in soft 
lithography techniques.  Importantly, PDMS is gas permeable allowing the exchange of 
oxygen gas across its surface [55].  Oxygen requirements vary greatly among the 
different cell types in culture.  Also, cells will react differently in ambient conditions with 
oxygen concentrations of 20-21% versus hypoxic conditions of 1-12% oxygen normally 
found in tissues of the body.  Determining the oxygen concentration is important to 
every experiment as the condition can greatly affect not only viability but also cellular 
behavior, morphology and differentiation and the rate of proliferation.  It has been 
shown that in hypoxic conditions the H1F1 pathway and NFkB pathway are activated 
inducing upregulation of protein synthesis and selective differentiation of cells that are 
regulated by dynamic changes in oxygen tension [56].  Metabolic changes in response 
to hypoxia are elicited through both direct mechanisms, such as the reduction in ATP 
generation, by oxidative phosphorylation or inhibition of fatty-acid desaturation, and 
indirect mechanisms including changes in isozyme expression through hypoxia-
responsive transcription factor activity [57].  Therefore, the ability to control gas 
concentrations in culture is an important factor and correlative to how cells response to 
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drug and with PDMS having a large surface to volume ration and reperfusion, it is 
possible to and easier to maintain set gas conditions.  PDMS is optically clear and has 
good fluorescence transmission down to ~275nm wavelengths allowing for cellular 
based microscopic evaluation on chip.  The PDMS based device is then layered and 
adhered to a glass microscope slide through a process of plasma etching.  Plasma 
etching is the process of exposing the surface of the PDMS device and a glass slide to 
oxygen gas at a high frequency electromagnetic field.  The surface of the PDMS and 
glass become polar and when the PDMS and glass slide come in contact they produce 
a covalent bond and adhere. 
 
 
Figure 3.  Dimensions of the posts and channel within device. 
(A) Image of the posts that make up the trap for the FNAB sample.  (B) A channel within device.  
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The design of the microfluidic network was created in L-Edit with the dimensions 
of the 10 microfluidic channels, trapping posts and inlets and outlets.  A transparency 
mask was created from the design file printed by a high-resolution printer.  The 
transparency mask was used in a soft-photolithography process using tridecafluoro-
1,1,2,2-tetrahydrooctyl trichlorosilane (Gelest Inc, Morrisville, PA) photoresist to create a 
silicon wafer master.  The silicon wafer was patterned with tridecafluoro-1,1,2,2-
tetrahydrooctyl trichlorosilane using standard photolithography techniques to create a 
mold for forming the channels and traps.  Uncured PDMS (10:1 base to curing agent 
weight ratio) was cast on top of the wafer to a thickness of 2 mm followed by degassing 
and curing at 65 ºC for 12 hours.  To ensure consistent thickness of the PDMS, a mold 
was designed and constructed (Figure 4).  The wafer was placed and clamped in 
between two planar metal casings fitted with O-rings.  PDMS was poured onto the wafer 
to a determined weight on a scale.  Once cured, the cast PDMS was peeled from the 
mold and fluidic inlet/outlet ports were made using a 1 mm biopsy punch for each 
channel.  Devices were cleaned with 70% isopropanol, rinsed with sterile filtered H20 
and further rid of debris by filtered forced air.  The PDMS surface of the device was 
rendered hydrophilic by exposure to oxygen plasma (Plasma Etch PE-100 Asher, 
Carson City, NV at 100 mTorr, 10 s, 150 W) to facilitate scaffold loading of a glass slide 
that seals the channel of the device.  Finally the device was sterilized by ethylene oxide 
gas and kept in their sterilized pouches until use.  Figure 5 [49] demonstrates the overall 
device features and the trap configuration in the 10 channels of the device.  Table 2 lists 
the requirements for the development of the device summarized in this section.  The 
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requirements will also serve to guide the performance of the device covered in 
proceeding chapters and will be referred to and discussed.  
 
 
Figure 4.  PDMS mold for consistent device height. 
Wafer is clamped between 2 metal casing that both have an O-ring seal to prevent loss of PDMS to 
edges.  The PDMS is cured on a level hot plate. 
 
 
Figure 5.  Microfluidic device design. 
(A) Exploded view of the prototype device  (B) Fully assembled PDMS device sealed to glass slide.  (C) 
Solid Works rendering of a channel in the device showing the central post arrangement used to trap 
FNAB tissue sample.  The channel is 10 mm long, 600 µm wide and 125 µm in height.  Each post is 150 
µm long, 75 µm wide and 125 µm in height [49]. 
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Table 2.  Tumor Trap Device List of Design Requirements and Specifications.  
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Previous Work Developing Microfluidics 
The design and fabrication methods used to develop the Tumor Trap Device was 
drawn on previous design and fabrication experience in developing a Membrane-
integrated Microfluidic Device for Imaging Cells.  As published in the journal of 
Biomicrofluidics [52], the multi-layer device was constructed to enable membrane 
separated cell culture for tissue mimetic in vitro model applications and 
pharmacodynamic evaluation studies.  The novelty of the device resides in the claims in 
the patent of the invention providing a method to fabricate microfluidic devices and 
methods for imaging cells.  The membrane device provides advantages for use in 
imaging of cells and subcellular compartments in an environment that mimics in vivo 
conditions.  Also, the microfluidic device can be used with a microscope equipped with 
an oil emersion objective lens [53].  The microfluidic device was developed via a unique 
combination of low profile fluidic interconnect design, substrate transfer methodology, 
and wet silane bonding.  To demonstrate the unique high resolution imaging capability 
of this device, we used oil immersion microscopy to image stained nuclei and 
mitochondria in primary hepatocytes adhered to the incorporated membrane [52].  
Additional experience was cultivated from the design and development and testing of a 
third microfluidic device for application of trapping and measuring the dielectric 
properties of three-dimensional multicellular spheroids over time using electrical 
impedance spectroscopy.  Microelectromechanical system techniques were used to 
embed opposing electrodes onto the top and bottom surfaces of a microfluidic channel.  
The system was validated for the devices ability to detect background conductivity 
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changes and dielectric particle diameter changes between electrodes using multicellular 
spheroids from a hanging-drop method protocol developed from MCF-7 cell lines [54]. 
 
Simulation of Fluid Flow in System Using COMSOL Multi-Physics Software 
To adequately test the design and functionality of the device for its ability to 
sustain consistent fluid without turbulence, a computer simulation-modeling tool is often 
advantageous for use to simulate whether the design specifies the intended 
functionality.  One important design feature to check with the simulation software is 
whether the fluid flow is laminar.  Parameters, such as velocity, can be calculated from 
the design when challenged with input values of specific flow rates delivered form an 
external source such as a peristaltic or syringe pump.  The system can also be 
evaluated at multiple interfaces for pressures and or stress created by such velocity 
profiles as fluid flows through the system. 
Computational modeling (COMSOL Inc., Burlington, MA) of a straight channel 
with posts arranged in a semi-circular staggered array was performed in three 
dimensions to simulate the laminar fluid flow.   The Newtonian fluid dynamic module 
solved the Navier-Stokes equation at steady state where Table 3 [49] summarizes the 
equations used.  The density and viscosity values were specified for water at room 
temperature (25°C).  The time to reach steady state for flow in the channel is almost 
instantaneous (~0.003 s to ~0.006 s) for flow rates between 50-500 µL/hr, confirmed by 
independent transient laminar flow simulations using the same geometry and flow rates 
experimentally studied in the device.  Therefore, solving the laminar flow as a stationary 
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phenomenon versus transient flow is a reasonable approximation.  The modeling 
parameters are listed in Table 4 [49]. 
 
Table 3.  Equations Employed During Computational Model. 
Name Equation 
Continuity Equation 
 
Momentum Equation 
 
u, velocity; ρ, density; P, pressure; µ, viscosity [49]. 
 
Table 4.  Modeling Parameters. 
Parameter Value Description 
ρ 998.2 kg/m3 density of water 
µ 1.003e-3 Pa*s dynamic viscosity of water 
u, velocity; ρ, density; kg/m3  kilogram per meter cubed; Pa*s, pascal second [49]. 
 
Channel layout and dimensions were taken from the device design.  A Poiseulle 
boundary condition was applied at the inlet, with a zero-pressure outlet and a no-slip 
fluid-wall interface.  These boundary conditions were imposed to solve for the laminar 
flow.  Mesh refinements were performed to minimize the flow flux between inlet and 
outlet.  After two successive refinements, resulting in 569,335 mesh elements, the error 
in flow flux ranged from 1.39% - 4.80%, increasing in error with higher flow rates.  
Further mesh refinements were tested on simulations using flow rates > 125 µL/hr with 
only a decrease in error of 0.5% leading to a 3-fold computation time increase.  An 
iterative geometric multi-grid (GMRES) algorithm solved the equations for the steady-
( ) 0* =∇ uρ
( ) ( )uµPuu*ρ ∇∇+−∇=∇
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state condition, while a direct backward differentiation formula (BDF) algorithm was 
required for the transient study. 
 
Computational Simulation Model and Validation 
To assess the accuracy of the simulation model performed with multiphysics 
software, licensed from COMSOL, we traced the fluid dynamic profile through the 
device for laminar flow and calculated velocity using 1µm diameter polystyrene 
fluorescently conjugated beads (Molecular Probes® FluoSpheres® beads, Life 
Technologies).  Beads were introduced into a reservoir in phosphate buffer solution for 
a final concentration of 1x106 beads/mL and pumped through the device using a 
peristaltic pump (Masterflex L/S Digital Drive, 100 RPM, 115/230 VAC) purchased from 
Cole Parmer and ran at flow rates of 15, 25, 65, 125, 250 and 500 µL/hr.  The flow was 
monitored and recorded by fluorescent microscopy using the Zeiss Axio 
ObserverZ.1/ApoTome.2 imaging system in the 580/605nm excitation/emission 
spectrum.  The resulting images were evaluated for determining laminar flow within the 
channel and each image frame was used to measure the length of the path the bead 
traveled divided by the exposure time to calculate for velocity. 
Results were used to validate the COMSOL simulations and gave us a clearer 
understanding of how various parameters such as flow rate, channel dimensions and in 
later studies, tumor size, would affect the FNAB tissue sample in the designed trap.  
Secondly, the testing results would give a clearer indication on whether the device 
design met the original specifications for use and if design modifications were needed. 
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Laminar Flow- Computational Simulation Model and Validation 
The flow rates chosen in the range of 15-500 µL/hr correspond to a Reynolds 
number range between 0.01-0.40, using ρ as the fluid density, u as the average 
velocity, DH as the hydraulic diameter of the channel and µ as the fluid dynamic 
viscosity.  Given that a Reynolds number below 2000 indicates laminar flow [32] for fluid 
in a pipe of diameter D, we concluded that the channel had laminar flow and the design 
did not impose turbulence.  The simulation was performed at a flow rate of 125 µL/hr.  
The simulation for velocity shows a profile of laminar fluid flow and no indication of eddy 
currents or large areas of dead volume around the traps (Figure 6A) [49].  Next, we ran 
the beads through the device and captured images of the fluid flow.  Figure 6B [49] 
shows an image of fluorescent beads flowing around the trapping posts; as seen in the 
model, similar streamlines are represented in the experiment, confirming a laminar flow 
around the posts. 
 28 
 
 
Figure 6.  COMSOL multi-physics software simulation of fluid velocity in channel through the device trap. 
(A) The simulation for velocity showing laminar fluid flow at a flow rate of 125 µL/hr.  (B) 10x magnification 
of a Texas Red fluorescent image superimposed on a phase contrast image of 1 µm diameter fluorescing 
beads flowing through channel at a flow rate of 125 µL/hr.  Image shows laminar flow around the trapping 
posts in channel [49]. 
 
Velocity of the Fluid Flow in Device with Fluorescent Bead Assay 
Next, we validated the computational model for velocity.  We took videos of the 
fluorescent beads flowing through the channel at a distance half way between the inlet 
of the channel and the trapping posts and at a z-axis location of 62.5 µm, which 
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corresponds to the center plane of the channel height.  We performed videos for all flow 
rates: 15, 25, 65, 125, 250 and 500 µL/hr (Figure 7).  Beads flowing in the center 25% of 
the channel width were measured at 81.8 s and 329.5 s, which correspond to the 
periods of maximum velocity in the peristaltic pump pulsation cycle.  The measured 
distances were then divided by the exposure time and averaged to yield a maximum 
velocity range of 0.00097 - 0.00136 m/s.  Maximum velocity was measured because it 
yields the maximum shear rate for a given flow rate.  When comparing the experimental 
and simulated maximum velocities, it was found that both values were in agreement, 
with a -3.56% error between them, showing that the computational model is a valid 
approximation for the fluid flow within the trapping device. 
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Figure 7.  Velocity measurements of beads in channel. 
Fluorescent 1um diameter beads were ran through microfluidic channels and imaged with Zeiss Axio 
ObserverZ.1/ApoTome.2 imaging system in the 580/605nm excitation/emission spectrum.  The path of 
the bead traveled was measured with the software from Zeiss, Zen Blue, and the lengths were calculated 
to determine final velocities. 
 
Conclusion 
We concluded that the device design, inlet and outlets and also channel and post 
dimensions of the trap, met the intended specifications for laminar flow without 
turbulence.  Secondly, we were able to evaluate the velocity profiles within the channel 
of the device and calculate the velocities for a range of flow rates within 25-500 µL/hr.  
Next, we will use the simulation tool for understanding if and how the FNAB samples will 
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affect the laminar flow and calculate the shear stress imposed upon the FNAB sample 
in the trap.  Two patent applications were submitted to the US Patent Office for the 
method and device design [50, 51].  
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CHAPTER THREE: 
FINE NEEDLE ASPIRATE BIOPSY ANALYSIS ON DEVICE 
 
Note to Reader 
 Portions of this chapter have been previously published in PLOS, 2017, 12(1):  
0169797 [49], and have been reproduced with permission from Public Library of 
Science.  PLOS is an open access journal and the legal disclaimer is listed in Appendix 
A.  The publication is listed in Appendix C. 
 
Chapter Synopsis 
The chapter herein describes the next steps taken to perform analysis of tumor 
samples on device.  In the previous chapter we designed built and tested the device for 
its ability to maintain consistent perfusion of media.  We used a software simulation tool, 
COMSOL, to determine the mechanical properties of flow.  We determined that the flow, 
when tested, was laminar.  We also determined that the posts, as designed with specific 
dimensions, did not disturb the flow.  Next, we needed to determine that once FNAB 
samples are placed within the trap of the microfluidic device the flow remains laminar 
and the shear properties of flow do not cause shear forces above levels that may kill or 
cause unwanted influences on the system.  From these studies we calculated an 
optimal flow rate to run the system with.  Second, we tested the system’s ability to fully 
perfuse drug into a FNAB sample.  Lastly, we validated the system with staurosporine 
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(SSP), a known PKC inhibitor that causes apoptosis.  We tested the model for cell 
death of tumor sample when exposed to SSP over a 5-day period compared to a 
negative control sample population. 
 
Establishment of Patient-Derived Xenografts 
The University of South Florida’s Institutional Animal Care and Use Committee 
(IACUC) and Institutional Review Board approved this study.  All animals were 
maintained and evaluated in accordance with IACUC standards care in pathogen-free 
rooms at the H. Lee Moffitt Cancer Center (Tampa, FL).  PDX mouse models were 
established using fresh tissue obtained at the time of resection from patients with lung, 
melanoma and bladder cancers and established as an F1 generation through 
subcutaneous implantation into four-week-old female immunodeficient hairless 
Crl:SHO-Prkdc-SCID-Hr-hr mice (Charles River Laboratories).  The patients provided 
written informed consent for the study.  The tumors from this initial passage are 
harvested and implanted subcutaneously into F2 generation.  Tumors were allowed to 
grow to a size of 1.5 cm, at which point they were harvested, divided into small 3 × 3 × 3 
mm pieces, and transplanted to an F3 generation.  At the end of the experimental 
protocol, the animals were sacrificed by cervical dislocation after carbon dioxide 
sedation. 
 
Fine Needle Aspirate Biopsy (FNAB) Procedure with Loading on Device 
The FNAB procedure was performed using a 25-gauge needle where the 
subcutaneous tumor was sampled from all areas of the tumor, as previously described 
[58, 59].  Following the procedure, a Diff-Quik (DQ) stain was performed on the smear 
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representative of all samples to both validate viable tissue captured in the biopsy versus 
necrotic cells that, for example, underwent karyolysis with a majority of cells being eosin 
stained.  Also, characterization of the pathology of the cancer was denoted by multi-
nucleus and if any bacterial contamination present.  FNAB tumor samples were 
received immediately after biopsy procedure and transported on ice in RPMI media 
(RPMI 1640, phenol red and sodium bicarbonate powder 25 mM HEPES, 10% heat 
inactivated fetal bovine serum, 1% (w/v) penicillin/streptomycin, 0.3 g/mL L-glutamine, 
sterile filtered before use).  The FNAB tumor samples were allowed to settle on ice and 
the supernatant, rich in lipids and necrotic debris, was discarded.  The samples were 
then centrifuged at 200xg for 10 minutes discarding the supernatant and resuspended 
with fresh media.  FNAB tumor fragments that were compact and dense measuring 
~300 µm in diameter, viewed by light microscopy, were selected for introduction into the 
device.  FNAB fragments are elastic and therefore able to deform to the confined space 
of the channel dimensions.  FNAB tumor samples were placed in the reservoirs 
attached to the peristaltic pump and perfused with complete media at a flow rate of 125 
µL/hr.  Media and or drug were retained in reservoirs individual to each channel covered 
with a 0.2 µm pore gas permeable membrane open to atmospheric conditions allowing 
oxygen to dissolve into media while maintain a microbial barrier.  The percent of 
dissolved oxygen in media was validated in prior multi-day experiments on platform with 
oxygen sensors placed at the inlet and outlet of the channel in the device (NEOFOX-
KIT-PROBE, Ocean Optics) and was found to be ~16% +2 which has been found to be 
within normal ambient ranges [60, 61].  Additionally, the amount of oxygen that could be 
supplied into a PDMS device per day, based on our device dimensions, was estimated 
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to be 3.5x10-5mol O2/device day [62, 63].  The oxygen within PDMS per day is sufficient 
to sustain FNAB biopsy with roughly 1000-2000 cells with a total respiration of sample 
to be 8.64x10-9mol/day.  Therefore, adequate oxygen is delivered to the FNAB sample 
per day if the system was stagnant but because the media is additionally renewed with 
flow rates of 125 µL/hr; oxygen is renewed more often in the device.  The temperature 
of the system was maintained at 37 °C by a microscope incubation chamber.  Figure 8 
depicts a schematic procedure overview of the FNAB process. 
 
 
Figure 8.  FNAB sampling procedure and placement into device. 
The FNAB sample is created by harvesting a patient biopsy and injecting the subQ sample into the 
hindlimb of a SCID mouse.  The tumor samples are transplanted to a F3 generation and sampled by a 
FNAB process and placed into the flow stream of a microfluidic device where it is kept within controlled 
environment. 
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Fluid Flow Testing with FNAB Tumor Sample 
 A model of fluid flowing in the channel of the microfluidic device was designed to 
understand how various parameters such as flow rate, channel dimensions and tumor 
size would affect the FNAB tissue sample in the designed trap.  A simulation model was 
constructed with tumor in the channel trap to determine if the laminar flow profile 
modeled, validated in Chapter 2, remained true once challenged with tumor in trap.  
Also, we calculated the average shear stress incurred on the tumor sample in trap to 
determine the optimal flow rate within the range of flow rates tested previously.  Lastly, 
the a simulation model was constructed to determine the optimal size of FNAB sample 
for use within the system. 
 
Shear Stress 
To assess the effect of shear stress and with varying degrees of channel 
occlusion with resistance of flow on the FNAB tumor sample in trap, we constructed 
plots of the average shear rate on the tumor perimeter for various flow rates and tumor 
sizes.  Plots were compared at multiple flow rates of 50-500 µL/hr for a single channel 
(600 µm by 125 µm channel cross section). 
To assess the shear stress on a tumor, we simulated an irregular-shaped tumor, 
trapped inside a channel by the posts.  The tumor was modeled with no-slip boundaries, 
which translates to no interstitial flow within the tumor.  A surface plot of the shear rate 
of a tumor occluding 50% of the channel at a flow rate of 125 µL/hr (Figure 9A) [49] 
shows areas with largest shear rate located by the posts, with an average shear stress 
of 0.257 dynes/cm2 around the tumor boundary.  A parametric study was performed to 
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evaluate the average shear rate experienced by the tumor at varying flow rates using a 
50% occlusion model.  It was found that in order to remain below a threshold of 0.4 
dynes/cm2, a physiological critical threshold for shear stress [45, 64]; for a tumor that 
occluded the channel by 50%, a flow rate of less than ~190 µL/hr was needed (Figure 
9B) [49].  Further, we simulated various tumor sizes that occluded the channel between 
50-90% at a flow rate of 125 µL/hr.  At this flow rate, it was found that tumors that 
occluded less than 70% of the channel width experienced an average shear stress less 
than 0.4 dynes/cm2 (Figure 9C) [49].  The effect of pressure was also calculated in the 
system and it was found that there was a negligible pressure drop across the tumor of 
5.812 pa. 
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Figure 9.  Simulation of shear stress on tumor trapped inside a channel. 
(A) Surface plot of the shear rate of a tumor occluding 50% of the channel at a flow rate of 125 µL/hr with 
an average shear stress of 0.257 dynes/cm2 around the tumor boundary. (B) Average shear stress 
experienced by the tumor at varying flow rates using a 50% occlusion model of tumor in channel. (C) 
Average shear stress experienced by tumor with occlusions of tumor in channel ranging from 50% - 90% 
at a flow rate of 125 µL/hr [49]. 
 
Laminar Flow 
Next, we challenged the laminar flow profile by adding FNAB tumor samples of 
different density, shape and size to the device channels to determine if occluding flow 
would cause turbulent flow.  FNAB tumor samples from PDX mice were biopsied as 
previously explained.  We tested lung adenocarcinoma, melanoma, and bladder 
squamous cell carcinoma.  Fluorescent polystyrene beads were flown into the channel 
at varying flow rates between 125 – 500 µL/hr.  Fluorescent imaging was performed to 
 39 
capture the flow profile of fluorescently conjugated polystyrene beads in channel.  It was 
found that properties of laminar flow in the channel were sustained with the addition of 
FNAB tumor fragments in channel trap.  Adding FNAB tumor fragments to the channel 
traps and therefore creating some degree of occlusion of fluid flow within the channel, 
created higher velocities at the sidewalls of the channel.  This was determined by 
measuring longer distances traveled in each frame seen by the fluorescent stream or 
path of the beads (Figure 10) [49].  However, we also found that the beads in the center 
of the channel at the fluid interface closest to the tumor showed little to no distance 
traveled within frames and therefore lower velocities.  These observations prompted 
further testing using smaller molecular weight drugs, such as doxorubicin HCl, to test for 
areas of stagnation at the fluid interface of the tumor and to further evaluate for 
convective properties with full fluid perfusion throughout the FNAB tumor sample.  
Doxorubicin HCl was chosen as a test model due to it having the benefit of 
autofluorescence and being able to be tracked by fluorescence microscopy as it diffuses 
through tissue.  As previously stated, vascular capillaries and tissues are known to have 
Reynolds numbers <100, resulting in predominantly diffusion based characteristics, over 
spatial distances of approximately 200 µm [29, 30] within which cellular metabolite 
uptake, gaseous exchange and waste removal occurs [31].  Instances where Reynolds 
numbers are > 2000 [32] for fluid moving in a circular channel and Re>10 for flow with a 
circular object in a fluid, the fluid flow becomes turbulent.  Turbulence can then create 
disturbances and higher shear forces creating fluid stresses on cells and or tissues 
within the microfluidic device resulting in cellular and or tissue destruction.  Secondly, 
tissues that are greater than 200 µm thick may rely on additional advective fluid forces 
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for where diffusion is limited.  Since our model will be using FNAB samples larger than 
200 µm thick we will need to test our model for diffusion limits and determine if active 
flow or advection aids in delivery of nutrients and or drugs throughout the FNAB sample 
and what those limits of tissue thickness may be.  
 
 
Figure 10.  Fluid velocity in channel through the device trap with various FNAB tumor samples. 
10x magnification of a Texas Red fluorescent image superimposed on a phase contrast image of 
fluorescing beads flowing at a rate of 125 µL/hr round a FNAB tissue sample of lung adenocarcinoma, 
melanoma and bladder squamous cell carcinoma [49]. 
 
Evaluation of Small Molecule Drug Perfusion in FNAB 
 A model of fluid flowing in the channel of the microfluidic device was designed to 
understand how various parameters such as flow rate, channel dimensions and tumor 
size would affect the FNAB tissue sample in the designed trap.  To assess the shear 
stress on a tumor, we simulated a tumor, trapped inside a channel by the posts (Figure 
8) [49].  To assess the accuracy of the simulation model performed with multiphysics 
software licensed from COMSOL, we tested the fluid profile through the device with 
1µm diameter polystyrene beads conjugated to a fluorophore with an 
excitation/emission wavelength of 580/605 nm.  With concerns of lack of interstitial flow 
at the tumor interface in the center of the channel, seen from results of the fluorescent 
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bead assay with FNAB tumor fragment in channel and concerns that diffusion limits with 
FNAB samples thicker than 200 µm (Figure 9) [49], we next tested the advective 
properties of fluid flow through FNAB tumor samples using a homogenous fluorescing 
solution.  We predicted that the size of the 1µm diameter fluorescent beads, previously 
used, did not accurately depict homogenous fluid flow.  Therefore, we opted to use a 
soluble small molecular weight compound to track interstitial flow and drug penetration 
throughout the FNAB tumor fragment.  We selected doxorubicin HCL (Sigma Aldrich, 
USA) for its natural fluorescence in a spectrum similar to FITC with an excitation of 480 
nm and an emission of 560-590 nm and a molecular weight of 579.983 g/mol [65, 66].  
Doxorubicin enters the nucleus where it interacts with DNA by intercalation and 
inhibition of macromolecular biosynthesis.  The planar aromatic chromophore portion of 
the molecule intercalates between two base pairs of the DNA, while the six-membered 
daunosamine sugar sits in the minor groove and interacts with flanking base pairs 
immediately adjacent to the intercalation site [67, 68].  This inhibits the progression of 
topoisomerase II, an enzyme that relaxes supercoils in DNA for transcription [69].  
Doxorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain 
for replication, preventing the DNA double helix from being resealed and thereby 
stopping the process of replication [70].  As a result to the DNA damage response, 
epigenome and transcriptome are deregulated in doxorubicin-exposed cells [71]. 
We hypothesized, if the bead assay was correct and the fluid path was restricted 
by the FNAB tumor fragment in channel with lower to no flow velocities in the center of 
the channel and higher velocities at the side walls of the channel, there would be 
evidence of fluorescent gradients of doxorubicin seen throughout the FNAB tumor 
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fragment.  Fluorescence intensities would be weak or nonexistent with little to no drug in 
cells of the tumor fragment residing in the central portion of the channel and higher 
intensities with greater drug concentrations in cells of the tumor fragment residing 
nearest the sidewalls of the channels.  Secondly, with flow restriction, the infusion of 
drug into cells would occur first in areas of the tumor that experience greatest flow, 
specifically, at the tumor interface where the tumor first meets the fluid front.  The cells 
located in the backside of the tumor fragment, specifically at the center of the channel, 
would experience a delay in drug infusion due to the lag time in flow and low to no flow 
velocities as demonstrated by the fluorescent bead assay.  Lastly, we wanted to 
determine diffusion limits of FNAB samples thicker than 200 µm and if the advective 
properties of flow would further drive fluid into the interior of the FNAB samples where 
diffusion alone may be limited. 
To test for drug penetration throughout the FNAB samples, specifically in the 
most interior central region, we selected lung adenocarcinoma FNAB tumor samples of 
various thicknesses taken from PDX mice as previously explained.  Doxorubicin HCL 
purchased from Sigma Aldrich was reconstituted with 10% dimethyl sulfoxide (DMSO) 
to a concentration of 1 mg/mL.  Doxorubicin was introduced into a reservoir of cultured 
media at a working dilution of 1 µM diluted with cell culture media, (RPMI 1640, without 
glutamine, phenol red and sodium bicarbonate powder) adding 25 mM HEPES, 10% 
heat inactivated fetal bovine serum, 1% (w/v) penicillin/streptomycin, 0.3 g/mL L-
glutamine sterile filtered before use.  The 1 µM doxorubicin solution was delivered by 
peristaltic pump at a flow rate of 125 µL/hr for a 24-hour period.  Fluorescent imaging 
was performed by a Zeiss Axio ObserverZ.1/ApoTome.2 inverted scope over a 24-hour 
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period to measure drug perfusion throughout the FNAB sample in device.  The drug 
solution was pumped into the channels with FNAB tumor fragments in trap.  A control 
condition of FNAB in trap primed with the doxorubicin solution was kept stagnant for 24 
hours and compared to an experimental group of FNAB in trap primed and continuously 
perfused for a period of 24 hours.  Over the 24-hour period, groups were continuously 
fluorescently imaged. 
Results from the control group showed little uptake of fluorescence with a 
majority of the cells taking up the doxorubicin solution being in the periphery within the 
initial hours of the experiment terminating with no fluorescence at the conclusion of the 
last 12 hours of the experiment.  However, because only cells of the periphery took up 
drug it is suggested that the drug was either diffusion limited into the interior of the 
FNAB sample or the cells experienced a concentration gradient of drug and availability 
was exhausted or the cells were able to actively pump the drug back out of the cell.  
The perfused group’s results indicated an evenly dispersed uptake of the drug into the 
all cells of the FNAB samples without indication of gradients demonstrated by an influx 
of green fluorescence into distinct clearly defined semi-circular membrane bound cells 
in all areas of the FNAB sample.  Fluorescent intensities of the drug were evenly 
distributed across the tumor sample occurring simultaneously in all areas of the tumor 
throughout the 24-hour period; fluorescence with similar intensities occurring at same 
time both in areas nearest the fluid front and areas of the back-end or lagging front of 
the FNAB (Figure 11A) [49].  Excitingly, we were also able to capture resulting apoptotic 
cellular behavior during the 24-hour period of drug infusion.  Apoptosis was signified by 
chromatin clumping and condensation with nuclear fragmentation and the formation of 
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apoptotic bodies evident from high intensity concentrations of the dye and foreign body 
formation [72] (Figure 11B) [49].  Apoptosis was seen in all regions of the tumor sample 
and occurred simultaneously at opposing ends of the flow both in cells located in the 
center of the tumor sample and at the sidewalls exemplifying the solution itself did not 
contain gradients nor did the FNAB sample experience limitations of which the center of 
the FNAB would not receive full drug perfusion.  Several trials of this experiment 
determined that a 300 µm would best serve as the optimal thickness of FNAB samples 
going forward and determined our sampling procedure for using a 25 gauge needle 
during the biopsy procedure and final measurements performed by microscopic 
evaluation and calculation by Zeiss Zen software. 
 
 
Figure 11.  Assessment of small molecule drug perfusion in a tumor FNA fragment using Doxorubicin 
HCL. 
(A) Drug perfusion after an 8-hour period showing distribution of drug indicated by green fluorescent 
intensity spatially similar throughout the FNAB tissue sample.  (B) Drug perfusion after a 24-hour period 
showing intensity peaks spatially similar throughout the FNAB tissue sample and the formation of 
apoptotic bodies [49]. 
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Evaluation of Large Molecule Protein Perfusion in FNAB 
Drug perfusion through the full FNAB tumor fragment was successfully 
demonstrated with a small molecular weight compound solution of doxorubicin HCl.  
The next step was to determine if larger molecular weight protein based molecules 
could penetrate the FNAB tumor sample during fluid perfusion.  To demonstrate large 
molecule perfusion through FNAB tumor samples we used protein antibodies that 
warranted specific recognition of a protein/protein interaction with the tumor tissue.  An 
antibody, conjugated to Cy5 fluorophores, raised against EpCAM that is expressed on 
the cell membranes of most carcinomas, and an antibody conjugated to FITC 
fluorophores prepared against CD44, another cell membrane protein expressed on 
tumors of epithelial origin, were used.  EpCAM and CD44 were diluted to a working 
concentration of 1:200 and introduced into the device with a flow rate of 125 µL/hr.  
Isotype controls for each antibody were purchased with the same fluorophore to indicate 
nonspecific binding in the device.  Fluorescent imaging was performed by z-axis plane 
evaluation with 20 µm spacing.  Figure 12 shows a central z-axis plane image of a 
FNAB sample over a 24-hour period of staining.  Antibody staining is widely dispersed 
throughout the FNAB sample showing different concentrations of both CD44 and 
EpCAM proteins in all areas of the FNAB samples.  Differential staining of the tissues 
exemplifies regional specificity of the tumor tissue.  Also, the staining of CD44 and 
EpCAM in the central z-axis position, which goes through the interior center of the 
FNAB samples, demonstrates that there is full perfusion of media throughout the whole 
FNAB tumor sample.  After a 4-hour perfusion of antibody solution of both EpCAM and 
CD44, the antibodies could be seen throughout the FNAB tumor sample [49].  Controls 
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in Figure 13A indicated that the isotype controls did not bind to the FNAB tumor 
fragments indicated by the absence of fluorescence throughout the FNAB tumor sample 
[49].  EpCAM and CD44 antibodies did, however, bind distinctively throughout the 
FNAB tumor sample as seen through multiple z-axis images with 40 µm spacing from 
the surface of the tumor (z/5), through the interior of the tumor (z/7 and z/9), with 
completion on the opposing side, 30µm from the opposing surface (z/11) (Figure 13B) 
[49].  Binding was specifically mediated by recognition through protein-protein 
interactions as seen with differential staining throughout each layer.  There was little to 
no staining in areas of high stromal concentration.  Therefore, staining was specific 
opposed to being inadvertently forced into the tissue by mechanical forces generated by 
flow in a nonspecific fashion and antibodies were able to reach the interior center of the 
FNAB samples. 
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Figure 12.  Twenty-four hour time point evaluation of antibody perfusion through the tumor FNAB on 
device. 
10x phase contrast image of FNAB sample in trap of device and 10x fluorescent z-axis image in center of 
FNAB 2-24 hours post the staining procedure using EpCAM (red-Cy5) and CD44 (green-FITC). [49]. 
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Figure 13.  Evaluation of antibody perfusion through the tumor FNAB on device. 
(A) 10x Phase contrast image of FNAB sample in trap of device and 10x fluorescent z-axis images (z5, 
z7, z9, z11) 24 hours post the staining procedure using isotype control antibodies for both EpCAM (red-
Cy5) and CD44 (green-FITC). (B) 10x Phase contrast image of FNAB sample in trap of device and 10x 
fluorescent z-axis images (z5, z7, z9, z11) 24 hours post the staining procedure using EpCAM (red-Cy5) 
and CD44 (green-FITC) [49]. 
 
 
Assessment of Tumor Viability 
Next, we sought to determine how long fresh FNAB tumor samples would remain 
viable in the device and also to characterize the working limitations of the viability dye, 
CalceinAM, and apoptotic antibody stain, CF594-AnnexinV.  The results from the 
viability experiments were then used to determine the optimal length of a drug treatment 
trial for later experiments. 
CalceinAM viability stains (Molecular Probes) and CF594-Annexin V (Biotium) 
antibody were both added to cell culture media with binding buffer for final 
concentrations of 5 µM for each dye.  The dye solution was then used to perfuse FNAB 
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tumor samples to assess for viability and apoptosis in real time continuously over the 
time course of experiments.  Fluorescent imaging was performed by a Zeiss Axio 
ObserverZ.1/ApoTome.2 inverted scope using a 378HE Green Fluorescent Protein 
(GFP) filter (excitation: 450-490nm /emission: 500-550nm) and a 45 Texas Red (TR) 
filter (emission: 540-580/excitation: 593-668nm) for CalceinAM and CF594-AnnexinV 
respectively.  ZEN 2012 software was used to calculate the sum of intensity units 
throughout the FNAB tumor fragments in each device channel.  Background and or 
auto-fluorescence was subtracted out from each summed value of intensity.  The sum 
of intensity values for both CalceinAM and CF594-AnnexinV were normalized for each 
FNAB tumor fragment by dividing the summed values of intensity of each emission by 
the size (area µm2) of the FNAB tumor fragment in each z-axis throughout the volume of 
the tumor fragment to give total relative fluorescent units (tRFUs) for each FNAB tumor 
fragment.  The health of each FNAB tumor fragment at the end of each drug trial was 
reported as a viability index factor (Vi) = GFP tRFUs (viability) / TR tRFUs (apoptosis) to 
normalize all samples across all test sessions. 
 For the experiment, FNAB tumor fragments were each placed in a channel of the 
device and perfused with circulating cell culture media with 5 µM CalceinAM Green and 
5 µM CF594-AnnexinV, as previously described in the methods section.  A baseline Vi 
analysis was performed on each FNAB tumor fragment after 12 hours of being in the 
device to determine the ratio of viable cells to apoptotic cells in each FNBA tumor 
sample.  Those fragments with a Vi of <0.9 were deemed as nonviable and rejected 
from further analysis.  FNAB tumor fragments were then continuously measured each 
day over a total period of 10 days.  It was found, with all samples, that after 6 days in 
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device the Vi decreased steadily with a sharp decrease in the tRFUs for the CalceinAM 
and a small less dramatic fluxuation in the tRFUs for the CF594-AnnexinV.  CalceinAM 
is a cell-permeant dye that can be used to determine cell viability in eukaryotic cells. 
Modification of carboxylic acids with AM ester groups results in an uncharged molecule 
that can permeate cell membranes.  Once inside the cell, the lipophilic blocking groups 
are cleaved through hydrolysis by nonspecific esterases in the cytoplasm of 
metabolically active and healthy cells, resulting in a charged form that fluoresces.  
CF594-AnnexinV is a 35-36 kDa protein that has a high affinity for phosphatidylserine.  
In normal membrane intact viable cells, phosphatidylserine is located on the 
cytoplasmic surface of the cell membrane.  In apoptotic cells, phosphatidylserine is 
translocated from the inner to the outer leaflet of the plasma membrane, making itself 
available for AnnexinV binding.  To determine if the decreasing tRFUs for CalceinAM 
was due to a decline in FNAB tumor sample viability or the working limitations of the 
CalceinAM dye, we re-challenged the system in several ways.  First, we added fresh 
FNAB tumor fragments to the channels containing the CalceinAM Green and CF594-
AnnexinV solution.  The newly added fresh FNAB tumor fragments did not take up the 
CalceinAM Green dye.  Next, we re-challenged the FNAB tumor fragments with 
CalceinAM Blue by adding a 5 µM concentration of CalceinAM Blue to the original 
circulating 5 µM CalceinAM Green solution.  CalceinAM Blue was added to rule out if 
the fluorescent capability of CalceinAM Green had extinguished either by photo-
bleaching due to continuous monitoring over the course of experiment and or quenching 
by use of the CF594-AnnexinV fluorophore.  The FNAB tumor fragments did not take up 
the CalceinAM Blue.  We then added a second round of fresh FNAB tumor fragments to 
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the same channels.  The second round of newly added fresh FNAB tumor fragments, 
without prior exposure to the original CalceinAM Green dye, showed a dramatic 
increase of CalceinAM Blue uptake into cells resulting in an increase of intensity values 
after a 4-hour period of incubation.  Last, to test substrate concentration limitations of 
CalceinAM at a 5 µM concentration over the 10-day experiment, we flushed the system 
from the re-circulating CalceinAM and CF594-AnnexinV dyes and reintroduced newly 
made 5 µM CalceinAM Green and 5 µM CF594-AnnexinV to the existing, previously 
exposed, FNAB tumor fragments in channels and also added fresh FNAB fragments to 
the channel.  The intensity values for CalceinAM Green increased slightly for the 
previously exposed FNAB fragments but only after a 48-hour period of exposure and in 
a limited number of cells in isolated regions of the FNAB tumor fragments.  The newly 
added FNAB fragments resulted in the uptake of dyes with strong intensity.  
Experiments and results are summarized in Table 5 [49].  Results indicated that the 
fluorophore, in the original solution containing CalceinAM Green, had extinguished and 
was not able to be detected.  Also, previously administered CalceinAM competitively 
blocked its cellular targets from binding newly added CalceinAM Green or CalceinAM 
Blue demonstrating that a working concentration of 5 µM was adequate for continuous 
binding in viable cells.  In addition, it was also seen that FNAB tumor samples sustained 
in the system over a 10-day period, continued to take up newly added CalceinAM dye 
when new cells were populated in the FNAB tumor fragments.  CF594-AnnexinV 
continued to fluoresce in the system with increased intensity peaks after 10 days.  We 
determined that the longevity of the fluorophore conjugated to the CalceinAM had a 
working limitation of 5 days either due to photo-bleaching and or quenching within the 
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system.  These results show that drug experiments should ideally be performed within 5 
days of placing the tumor tissue in the microfluidic device. 
 
Table 5.  Calcein AM Dye Validation and FNAB Sample Viability Assessment 
 Original FNAB 
Newly Added FNAB 
(without prior exposure) 
 
Original CalceinAM 
Green/AnnexinV Solution 
Decreased green intensity 
after 5 days No dye uptake 
Original CalceinAM 
Green/AnnexinV Solution 
+ CalceinAm Blue 
Solution 
No blue dye uptake Increased blue intensity 
Flushed + New 
CalceinAM 
Green/AnnexinV Solution 
Minimal green intensity Increased green intensity 
[49] 
Validation Testing Using Staurosporine Drug Model 
Next, week sought to test FNAB samples on device with a known apoptotic 
inducer, staurosporine (SSP), so that we can model drug induced apoptosis against 
viable controls.  This method of test verification would allow us to assess viability versus 
death in using the representative CalceinAM green viability stain and AnnexinV 
apoptotic stain.  This model would also allow us to evaluate the stains ability to capture 
viable FNAB samples and those that should show death after exposure to SSP and how 
best to present those differences.  SSP is a microbial alkaloid, isolated from 
Streptomyces sp. cultures. SSP has demonstrated antiproliferative activity in several 
human cancer cell lines [73]. SSP’s mechanism of action on cancer cells is to induce 
G2/M cell cycle arrest and to modulate G1 arrest of the cell cycle [74]. Progression 
through the cell cycle is controlled by cyclins, cyclin dependent kinases and metastatic 
tumors often have high levels of cyclins and cyclin dependent kinases.  SSP is an 
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inhibitor of those protein kinase C and cyclin-dependent kinases [75].  SSP was 
reconstituted with DMSO to a stock concentration of 10 mM.  A further working solution 
of 50 µM was made diluted with RPMI media.  Earlier experimentation with FNAB 
samples on 24 well plate proved that for 90% death a concentration of 50 µM was 
needed to penetrate FNAB samples and produce an apoptotic effect with 48-72 hours of 
exposure.  Also, a dosing experiment was carried on device for 1,10, 25 and 50 µM 
concentrations.  Results indicated that for a 5-day experiment with 90% death a 
concentration of 50 µM was needed.  Similar concentrations have been used in 
microfluidics with perfusion and necessitated 7 days for similar results. [43].  
Patient derived lung adenocarcinoma FNAB tumor samples taken from xenograft 
mice were injected into each channel of a device and perfused with RPMI media with 
CalceinAM viability dye and apoptotic CF594-AnnexinV antibody dye, as previously 
described, and evaluated for baseline health over the course of a 12-hour period to 
assess for viability and apoptosis prior to start of each experiment.  After the 12-hour 
viability assessment, with samples showing a Vi ratio >0.9, with approximately as many 
viable cells in the FNAB tumor sample than apoptotic cells, FNAB tumor fragments were 
then exposed to their assigned experimental condition.  The test groups included a 
negative control group, conditioned with media and 0.1% DMSO and a drug treatment 
group, conditioned with 50 µM SSP.  A total volume of 1.5 mL in each reservoir 
containing either test condition was discretely circulated through each channel of the 
device containing a single FNAB tumor ~300 µm diameter fragment for a treatment 
period of 5 days.  Each experiment was run continuously for a treatment period of 5 
days.  Each condition was run in triplicate for every device session tested totaling 6 
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experimental sessions (n=18; each treatment group).  Images were taken of each FNAB 
tumor fragment for every 24-hour time point over the course of 5 days.  The images 
were later analyzed for the tRFUs of CalceinAM and CF594-AnnexinV.  A viability index 
(Vi) was calculated for each sample at every time point and then averaged across all 
samples within a group for each time point.  Each group was evaluated by a repeated 
measures ANOVA analysis for Within-Subjects Effects calculated across the 5-day 
testing period.  A Greenhouse-Geisser correction was performed for violation against 
sphericity. 
Results for each group indicated a significant linear change over the course of 
the 5-day experiment (p=0.003) with increased standard error at days 4 and 5 for the 
negative control group and days 1, 2 and 3 for the SSP treatment group.  Increased 
standard error during those days was due to greater variability in Vi across samples 
within a treatment group.  The means of each group were then compared at each time 
point for statistical significance.  On average, the Vi for the negative control groups 
increased as the testing session continued over the course of 5 days, but decreased for 
the SSP treatment group (Figure 14) [49] with a statistical significance of p=0.0355 for 
day 1 and p=0.0001 for days 2-5.  Figure 15 [49] shows a three-dimensional view of the 
representative FNAB tumor fragments from both the negative control groups and the 
SSP treated groups at days 1 and day 5.  Each view shows the ratio of viable cells 
(green) to apoptotic cells (red) and also how they are spatially organized and distributed 
within the FNAB tumor fragments.  The representative negative control FNAB sample at 
day 1 has a greater concentration of viable cells throughout the FNAB tumor fragment 
than the concentration of CF594-AnnexinV antibody protein on apoptotic cells, found 
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mostly at the periphery of the sample.  At day 5, the negative control FNAB tumor 
fragment had an increase in apoptotic cells at the periphery but with a majority of the 
cells within the FNAB tumor fragment being viable.  The SSP treated sample on day 1 is 
highly populated with green viable cells with a distinct subpopulation of apoptotic cells in 
the right periphery of the sample.  At day 5, the apoptotic subpopulation of cells seen in 
day 1 was lost and the majority of the viable cells seen in day 1, overtime, became 
apoptotic in day 5.  Apoptotic cells at day 5 were located both in the periphery and the 
center of the FNAB tumor fragment.  A histogram, to the left of each image, shows the 
intensity values of the relative fluorescence units (RFUs) across the x-axis on a scale of 
0 – 4000 and the y-axis scale for distance (µm).  Each spike in color on the histogram is 
measured across the corresponding x-axis for a comparable intensity value.  On day 1, 
the negative control had an average of 2500-3000 RFUs of green fluorescent protein 
(GFP) representing viability of CalceinAM staining, and 500-1000 RFUs of Texas Red 
(TR) representing apoptosis of CF594-AnnexinV staining.  On day 5, the negative 
control group still had an average 2500-3000 RFUs of GFP with an average of 1000-
2000 RFUs of TR.  The percent of apoptotic cells at day 1 for the negative control group 
was <5% of the total volume of the tumor compared to day 5 with 20% apoptotic cells.  
On day 1, the SSP treated group had an average 2000-2500 RFUs of GFP with an 
average of 500-1000 RFUs of TR.  On day 5, the SSP treated group had an average 
1000-2000 RFUs of GFP with an average of 2500-3000 RFUs of TR.  The percent of 
apoptotic cells at day 1 for the SSP treated group was <5% of the total volume of the 
tumor compared to day 5 with >70% of apoptotic cells.  The histograms serve to relate 
the intensities across all samples and also where in the sample the highest values of 
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live or dead stain are most localized depicting the ratio of live to dead cells in each 
FNAB sample. 
 
 
Figure 14.  Comparison of the calculated viability index of the tumor FNAB samples during 5 days of 
treatment. 
Comparison of the mean averaged VI of negative control group and staurosporine treated group from the 
baseline over the 5 day exposure period with n=18 within each group.  The difference in means between 
each treatment group was statistically significant, except for the baseline [49]. 
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Figure 15.  A 3-dimensional view of a representative FNAB samples for non-treatment and staurosporine 
treated groups. 
Negative control and staurosporine treated groups at day 1 and day 5 with their respective histograms to 
the left of each sample show the intensity profiles of relative fluorescence units of GFP (CalceinAm) and 
Texas Red (AnnexinV).  The scale bar on the x shows intensity in relative fluorescence units (0-4000 
RFUs) and the scale bar on the y axis of the histogram images shows the distance (µm) [49]. 
 
Statistical Significance 
The mean and standard error of each treatment group was calculated with n=18 
samples.  A repeated measures ANOVA analysis was performed for Within-Subjects 
Effects across the 5-day testing period for both groups.  A Greenhouse-Geisser 
correction was performed for violation against sphericity. Sphericity is an assumption 
that the variances of the differences between all possible pairs of groups are equal. If 
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sphericity is violated, then the variance calculations could result in an inflated F-ratio 
with the proportion of rejections of the null hypothesis larger than the α-level when the 
null hypothesis is true.  In order to minimize this problem, Greenhouse-Geisser 
procedure corrects the deviation to sphericity by using an index to correct the number of 
degrees of freedom of the F-distribution [76].  To determine the significance between 
groups, a Student’s two-tailed t test was performed from the calculated mean and 
standard deviation of each treatment group. P-values less than 0.05 were considered 
statistically significant. 
 
Conclusion 
Herein we tested the system’s ability to maintain laminar flow within device with 
FNAB samples in trap.  We found that the flow was laminar and when tested further, 
small molecular compounds such as drug are able to perfuse through the FNAB 
samples therefore setting the ground work for a model that can consistently test drug 
within FNAB tumor samples with the true understanding of the parameters for which the 
system operates and importantly how the drug interacts with the tumor sample.  
Second, we also determined and calculated for the optimal flow rate within the system 
so that undo shear forces do not influence the viability or prove to insult the FNAB 
samples with extraneous effects.  Also, we were able to determine that we were able to 
use large protein antibody stains within the system to characterize the samples with 
identifying surface protein markers on cells within the FNAB sample.  Identifying which 
cells respond to treatment is an important and valuable tool offering clinicians insight to 
how stem cells, fibroblast or immune cells may respond to drug on varying levels.  
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Lastly, we showed with great significance that the model was able to replicate results in 
using a known PKC inhibitor, SSP, to cause apoptosis over a control group. 
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CHAPTER FOUR: 
CHEMOTHERAPY MODEL	
 
Note to Reader 
 Figures in this chapter have been previously published in PLOS, 2013, 8(3):  
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2012, 2(10): doi10.1158/2159-8290.cd-12-0387 [78], and have been reproduced with 
permission from the American Association of Cancer Research.  The letter of 
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2014, 4(11): 10.1158/2159-8290.cd-14-0462 [80], and have been reproduced with 
permission from the American Association of Cancer Research.  The letter of 
permission to reprint is listed in Appendix A. 
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Chapter Synopsis 
Herein this chapter, we move the testing from verifying performance of the device 
to validating clinically relevant drug models tested in clinic and alongside mouse 
models.  Choosing the right model implied being cognizant of varying levels of drug 
response based on the genetic makeup of each tumor and thus knowing the history of 
how each tumor responded to treatment both in the clinic and in mouse.  History of drug 
response was very important in defining the parameters of testing outcomes on device.  
We chose targeted drugs, MK-1775; a Wee1 inhibitor and Erlotinib; protein kinase 
inhibitor for EGFR associated tyrosine kinase, so that we could verify each sample had 
the targeted mutation or associated protein that the drug targets when evaluating drug 
response.  Data was used from prior testing models using cellular assays and mouse 
models to compare the results using the same samples on the device performed on a 
later date. 
  
Drug Model MK-1775 
	
Osteosarcoma 
Sarcomas are cancers that arise from cells of mesenchymal origin such as bone, 
cartilage, fat, muscle, vascular or hematopoietic tissues.  Each year, about 1,000 new 
cases of osteosarcoma are diagnosed in the United States and osteosarcomas account 
for about 2% of childhood cancers, but they make up a much smaller percentage of 
adult cancers.  About 450 of these are in children and teens and most osteosarcomas 
occur in children and young adults between the ages of 10 and 30.  Teens are the most 
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commonly affected age group, but osteosarcoma can occur in people of any age.  
About 10% of all osteosarcomas occur in people over the age of 60 [1].  The treatment 
of sarcomas frequently involves neoadjuvant chemotherapy, before surgery, and 
adjuvant chemotherapy, after surgery, with a lesser degree of use of radiation therapy.  
Chemotherapies include:  high-dose methotrexate, doxorubicin, cisplatin, ifosfamide 
and etoposide.  Such chemotherapies are dangerously toxic with many side effects and 
are problematic for children.  Therefore, a more targetable approach with less side 
effects are needed for the treatment of childhood osteosarcomas. 
	
Cell Cycle and Mechanism of Action of MK-1775 
DNA damage pathways play an essential role in the survival of tumor cells.  
Cancer therapies target cells that are actively undergoing the cell cycle, as the DNA is 
vulnerable and exposed during this process of cellular division or proliferation.  DNA 
exposure makes the cells further susceptible to damage by antineoplastic drugs and 
radiation.  Checkpoints within the cell cycle such as at G1 and G2 monitor and regulate 
the progression of the cell through the mitotic process and prevent cell cycle 
progression at these points allowing for necessary DNA repair processes to ensue.  The 
cell cannot proceed to the next phase until checkpoint requirements are met to ensure 
that damage is not passed on.  Unlike normal cells, most p53 deficient or mutated 
human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint 
and these cells rely on the G2 checkpoint for DNA repair to damaged cells [81].  MK-
1775 is a small molecule inhibitor of the tyrosine kinase Wee1 with potential 
antineoplastic sensitizing activity.  MK-1775 selectively targets and inhibits Wee1, a 
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tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (Cdk1) to inactivate the 
Cdc2/cyclin B complex, an essential regulatory step in the G2/M transition.  The proper 
regulation of Cdc2 requires an activating phosphorylation on its threonine-161 (Thr-161) 
and inhibitory phosphorylation on threonine-14 (Thr-14) and tyrosine-15 (Tyr-15) [82].  
The Tyr-15 phosphorylation maintains the complex in an inactive state if there is 
damaged DNA in the cell.  Cdc2 activation through removal of its inhibitory phosphate 
by Cdc25 phosphatases allows cells to enter mitosis [83].  Inhibition of Wee1 activity 
prevents the phosphorylation of Cdc2 and impairs the G2 checkpoint with potential to 
push the cell into mitotic catastrophe [84].  This may lead to apoptosis upon treatment 
with DNA damaging chemotherapeutic agents.  
	
Previous Work Performed with MK-1775 
MK-1775 is the first reported Wee1 inhibitor with high potency, selectivity and 
oral bioavailability and is currently in several clinical trials.  Several studies have 
demonstrated that pharmacological inhibition of Wee1 by the small molecule kinase 
inhibitor MK-1775 leads to removal of Cdc2 phosphorylation at Tyr15 in tumor cells.  
MK-1775 has been reported to induce anti-tumorigenic effects in different cancer types 
that harbor p53 mutations when combined with cytotoxic agents [85-88]. 
In previous work it was shown that MK-1775 had a cytotoxic effect on sarcomas 
as a single agent independent of p53 mutation status and Wee1 inhibition by MK-1775 
resulted in activation of Cdc2, as assessed by decreased Tyr15 phosphorylation, 
unscheduled mitotic entry and significant cell death in sarcoma cell lines as well as in 
patient-derived sarcoma tumors [89].  Also, more current data compared the therapeutic 
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efficacy of MK-1775 alone and in combination with gemcitabine in different types of soft 
tissue and bone sarcomas.  Results demonstrated that MK-1775 showed its cytotoxic 
effect in sarcoma cells as a single agent in a p53 independent manner and representing 
a promising therapeutic agent in treatment of sarcoma [77]. 
Work performed in our lab used an osteosarcoma PDX model to assess the anti-
tumorigenic effect of MK-1775 alone or in combination with gemcitabine.  Previous 
experiments with osteosarcoma PDX showed that a positive response to drug does not 
always correlate with changes in tumor size in mesenchymal tumors, such as 
osteosarcomas, due to hyalinization.  Therefore the lab partnered to use MRI to monitor 
drug-mediated changes in tumor growth of subcutaneous implanted osteosarcomas and 
correlate with changes in consistency as shown Figure 16 [77].  Implanted tumors in 
vehicle control treated animals grew rapidly while gemcitabine treated animals produced 
less than 50% inhibition of tumor growth and single agent MK-1775 treatment resulted 
in ~75% inhibition of tumor growth.  Combination treatment of gemcitabine and MK-
1775 caused ~80% decrease in total tumor volume compared to control.  Interestingly, 
MK-1775 and combination treated animal groups showed an increased mineralization in 
tumors.  Western blot analysis of FNAB samples taken from mouse before treatment 
and 6 and 24 hours after treatment resulted in an increase in cdc2y15 indicative of drug 
response.  Hematoxylin & Eosin stain showed no change in gemcitabine treated group 
compared to vehicle control group on day 15 with only a slight increase in apoptotic 
activity.  MK-1775 treated group showed an increase in bone formation of ~50% and an 
increase of 75-90% in the combination treated group.  C-caspase was used to assess 
apoptotic activity for cellular death and results showed a slight increase of 20% in the 
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gemcitabine treated group, 50% increase in the MK-1775 treated group and 75-90% in 
the combination treatment group of MK-1775 and gemcitabine.  All groups showed an 
increase in γH2AX with a greater increase in the gemcitabine treated group consistent 
with G2/M cell cycle control mechanisms for DNA repair. 
 
 
Figure 16.  MK-1775 as a single agent and in combination with gemcitabine shows antitumor activity in 
human osteosarcoma PDX. 
FNA biopsies were taken before and 6 and 24 hours after treatment, and cell extracts were prepared to 
assess expression levels of CDC2Y15 by Western blot, b-Actin expression was used as loading control.  
Representative T2-weighted MRIs show increased tumor volume at day 15 in control and gemcitabine 
treatments compared to MK-1775-treated and combination-treated animals.  H&E-stained paraffin 
sections were prepared to assess microscopic features of cell death and differentiation representative 
micrographs.  Cleaved-caspase 3 images show high immunoreactivity in the MK-1775 and combination 
treatments compared to control and gemcitabine treatment.  stained for cH2AX show high 
immunoreactivity in gemcitabine, MK-1775, and combination treatments compared to controls [77]. 
 
Drug Model MK-1775 and Gemcitabine Tested on Device  
Using the previous results tested in the lab on animal models as a standard we 
then tested the device platform for similar results.  We hypothesized that the 
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gemcitabine and combination gemcitabine and MK-1775 treatment groups should have 
an increase in apoptotic activity and a decrease in viability compared to the vehicle 
control groups tested on device.  FNAB samples taken from osteosarcoma PDX mouse 
models where placed in channels of the device and tested in triplicate for a period of 48 
hours.  A Hoechst counter stain (ThermoFisher Hoechst 33342 10mg/mL) was used in a 
final concentration of 1/1000 to trace the viable nuclei in each FNAB sample countered 
to SYTOX Green (ThermoFisher) dead stain used at a final concentration of 1uM in 
solution.  The stains were added to the circulating cell culture media used to perfuse 
FNAB tumor samples.  Four conditions, vehicle control of 0.1% DMSO, 3uM 
gemcitabine, 1uM MK-1775 and combination of 3uM gemcitabine and 1uM MK-1775, 
were used as the treatment groups.  Each treatment group was tested in triplicate for a 
total of three FNAB samples tested discretely for a period of 48 hours.  Images were 
taken at the conclusion of the experiment after 48 hours and 100uL aliquots were taken 
from the circulation of each sample and frozen down in liquid nitrogen for testing lactate 
dehydrogenase and mass spectrometry analysis.  Fluorescence imaging was performed 
by a Zeiss Axio ObserverZ.1/ApoTome.2 inverted scope using a 49 DAPI filter 
(excitation: 365 BS FT 395/emission BP: 445/50) and 378HE Green Fluorescent Protein 
(GFP) filter (excitation: 450-490nm /emission: 500-550nm).  Results indicated that the 
combinatory treatment group of gemcitabine and MK-1775 and MK-1775 alone had the 
most death concluding the 48-hour experiment compared to vehicle control group.  The 
gemcitabine and control both showed 10-20% cell death.  The combinatory treatment 
group had 50-60% death and the MK-1775 treatment group had 70-90% death (Figure 
17). 
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Figure 17.  Fluorescent images of MK-1775 and Gemcitabine drug model tested on device. 
Osteosarcoma FNAB samples from xenograft mouse models tested on device with vehicle control, 1µM 
MK-1775, 3 µM Gemcitabine and combinatory treatment of both 1µM MK-1775 and 3 µM Gemcitabine.  
Blue stain is Hoechst 33342 for live cell and SYTOX Green for dead cell. 
 
Aliquots taken from the experiment were then tested for LDH across samples.  
The Pierce LDH Cytotoxicity Assay Kit (Thermo Fisher) measures extracellular LDH in 
culture media using an enzymatic reaction that results in a red formazan product, which 
can be measured spectrophotometrically.  Lactate dehydrogenase (LDH) is a cytosolic 
enzyme that is an indicator of cellular toxicity.  Results (Figure 18) show that the MK-
1775 and combinatory group had increased LDH compared to gemcitabine treatment 
groups and vehicle control groups.  All groups showed a decrease and leveling out of 
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LDH levels at and after 48 hours.  Results from this experiment showed similar results 
to the experiments performed on mouse model that were previously described to have 
synergistic activity with a heightened cytotoxic response for combinatory therapy.  It is 
unclear why gemcitabine had a lower response in device and is hypothesized that early 
examination of the FNABs within a 48-hour period may have recovered within the G2/M 
checkpoint to continue proliferative activity and or did not have a long enough 
evaluation period for detection of apoptotic activity.  Therefore, a longer testing period 
may be needed for possible delayed apoptotic events when testing with gemcitabine. 
 
 
Figure 18.  LDH concentration of osteosarcoma FNAB samples tested on device with MK-1775 and 
gemcitabine. 
Control samples showed a declining concentration of LDH through 36 hours with a resulting increase at 
48hrs.  Gemcitabine treated groups had a similar profile to control group with a slight increase in 
concentration of LDH over control group.  MK-1775 and combination treated groups showed a significant 
change in concentration of LDH compared to control groups at 36 and 48hrs with the combination group 
having a higher concentration of LDH at the conclusion of 48hrs. 
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Next, we analyzed the aliquots taken from the cultured media of the MK-1775 
gemcitabine and combinatory test samples, and analyzed them for active metabolites of 
the drugs.  As gemcitabine is metabolized it is converted intracellularly to active 
diphosphate (dFdCDP) and triphosphate (dFdCTP) metabolites, with deoxycytidine 
kinase being the rate-limiting enzyme [90, 91].  Gemcitabine is also metabolized to its 
inactive metabolite 2′,2′-difluorodeoxyuridine (dFdU) in liver, kidney, blood and other 
tissues [92].  About 99% of dFdU is subsequently excreted by kidney [93].  Gemcitabine 
and dFdU have been shown to have linear pharmacokinetics over the dose range of 
87–2500 mg m−2, but the conversion of gemcitabine to dFdCDP and dFdCTP is 
saturated at high concentration of gemcitabine [94, 95].  We wanted to determine that 
the results we detected from the live/dead stain were coincidental with the effects of the 
drug looking for drug metabolism in each sample.  Samples were run through liquid 
chromatography mass spectrometry (LC-MS) and distinct repeated profiles of drug 
metabolite triphosphate (dFdCTP) were found in all gemcitabine-tested samples and 
therefore determined that drug was metabolized within all samples.  Samples were 
compared to standards and database search with m/z value.  Excitingly, we also 
detected an unknown reproducible metabolite selected in the MK-1775 profile ran 
alongside MK-1775 standard hinting that an active metabolite was evident in the MK-
1775 drug tested samples (Figure 19).  The untargeted metabolite’s m/z value was 
searched against a database for having a molecular weight within a specified tolerance 
range of a group of ions likely to originate from the same compound.  In LC-MS-based 
metabolomics, multiple peaks in LC-MS data with distinct m/z values often represent 
one metabolite.  Similar retention times, due to the presence of isotopes, adduct and 
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neutral loss fragments and the ions from the same compound share similarly shaped 
elution profiles.  Mass differences of adducts/isotopes from their monoisotopic neutral 
forms can be calculated and used to search against metabolite databases.  Verification 
for the identity of an unknown metabolite ultimately requires the standard to be injected 
into the biological sample to compare their MS/MS spectra and retention times [96].  
Further analysis and testing was needed to validate the metabolite as a discovered 
active metabolite for the drug, MK-1775. 
 
 
Figure 19.  LC-MS of MK-1775 and potential metabolite. 
Plot shows a reoccurring metabolite for an unknown metabolite for MK-1775 samples and in combination 
with Gemcitabine. 
 
	
	
 
 71 
	Drug Model Erlotinib 
 
Non-Small-Cell Lung Cancer 
The American Cancer Society estimates that in 2017 there will be about 222,500 
new cases of lung cancer and about 155,870 deaths in the United States.  The overall 
5-year survival rate of lung cancer is lower than 14% and only one third of patients are 
eligible for surgical resection with curative intent [1].  Non-small-cell lung carcinoma 
(NSCLC) is a cancer of the epithelium and the most common types of NSCLC are 
squamous cell carcinoma, large cell carcinoma and adenocarcinoma.  Adenocarcinoma 
of the lung is currently the most common type of lung cancer in lifelong nonsmokers and 
accounts for approximately 40% of all lung cancers [1].  Adenocarcinomas are more 
often a cancer of the periphery and starts in secretory cells.  Squamous cell carcinoma 
accounts for 25% of lung cancers.  Squamous cell carcinoma starts in cells that line the 
inner airways of the lungs and is most often centrally located in the bronchus.  Large 
cell carcinoma is undifferentiated and can be found anywhere in the lung and grows and 
spreads more quickly than other types.  Large cell carcinoma accounts for 10-15% of 
lung cancers. 
	
Mechanism of Action of Erlotinib 
NSCLC exhibits mutational activation of the epidermal growth factor receptors 
(EGFR) tyrosine kinases (EGFR-TKI) or of those with a chromosomal translocation of 
anaplastic lymphoma kinase (ALK) making them constitutively active.  Systemic cancer 
therapy has shifted from broad cytotoxic conventional treatments to targeted therapy 
due to the discovery of oncogenic drivers.  In patients with EGFR-mutant lung cancer 
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with advanced disease, treatment with an EGFR kinase inhibitor (erlotinib or gefitinib) is 
superior to standard cytotoxic therapy [97].  Although successful at first, single agent 
therapies are not curative due to acquired treatment resistance.  Over time, cancer cells 
become more resistant to chemotherapy treatments.  Some of the cells that are not 
killed by the chemotherapy mutate and become resistant to the drug by selective 
advantage.  Once they multiply, there may be more resistant cells than those that are 
sensitive to chemotherapy.  A cancer cell may produce hundreds of copies of a 
particular gene due to amplification triggering an overproduction of protein that renders 
the anticancer drug ineffective.  Cancer cells may learn how to repair the DNA breaks 
caused by some anti-cancer drugs.  Also, cancer cells may pump the drug out of the 
cell using p-glycoprotein or altogether stop taking in the drugs because the protein that 
transports the drug across the cell wall stops working or develops a mechanism that 
inactivates the drug.  In approximately 50-60% of cases, the mechanism of acquired 
resistance to EGFR-TKI therapy is the acquisition of a second site T790M “gatekeeper” 
mutation in the kinase domain of EGFR, in addition to the primary activating kinase 
domain mutation [98, 99].  The second site T790M mutation in EGFR alters the binding 
of erlotinib and gefitinib to the ATP-binding pocket and therefore these inhibitors are 
unable to block EGFR signaling [78].  Other mechanisms of acquired resistance to 
erlotinib and gefitinib include the following:  upregulation of the AXL kinase in 
approximately 20-25% of cases; amplification of the MET kinase in approximately 5% of 
cases; activating mutations in the phosphoinositide 3-kinase (PI3K), PIK3CA gene in 
approximately 5% of cases; and histologic and phenotypic transformation to small-cell 
lung cancer in approximately 5% of the cases [78, 98-101] (Figure 20) [78].  Although 
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EGFR mutations are associated with an enhanced sensitivity to EGFR-TKIs, not all 
respond to this line of therapy and confer resistance.  Mutations of KRAS, which occur 
in 20–30% of NSCLCs, seem to confer resistance to EGFR-TKIs and have been 
reported to be mutually exclusive with EGFR or HER2 gene mutations [102].  KRAS is a 
downstream mediator of EGFR signaling and confers constitutive activation of the 
signaling pathway without EGFR ligand activation.  Other mechanisms of resistance to 
EGFR inhibitors involve activating mutations of the PI3K/PTEN/AKT pathway.  
Phosphatidylinositol 3-kinase (PI3K) is an activator of Akt, which regulates cell survival 
and therefore oncogenesis and progression of human lung cancers.  It is well 
established that PI3K is activated by the stimulation of receptor tyrosine kinases [103].  
PIK3CA mutations appear to be indicators of resistance and poor survival in NSCLC 
patients treated with EGFR-TKIs25 [104].  These findings suggest that several different 
mutations other than of the EGF receptor regulate the sensitivity of NSCLC to targeted 
therapy (i.e. EGFR-TKIs) and therefore next generation treatments need to profile these 
specific patient mutational profiles for more effective and lasting therapies without 
incursion of resistance. 
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Figure 20.  Mechanisms of acquired resistance to EGFR inhibitors and emerging pharmacologic 
approaches to overcome resistance. 
A, the relative frequency of specific oncogenic driver mutations in lung adenocarcinomas. Red wedge 
indicates the frequency of somatic activating mutations in EGFR (L858R or in frame exon 19 deletion). B, 
the spectrum and frequency of known drivers of acquired resistance to EGFR inhibitor therapy in lung 
cancer. C, schematic of pathways to EGFR inhibitor acquired resistance and pharmacologic approaches 
in development to overcome them. EGFR T790M mutation is the dominant driver of EGFR inhibitor 
resistance (50%–60%). [78]. 
 
Previous Work Performed with Erlotinib Drug Model 
Our previous work developed methods to predict the efficacy of targeted agents 
in PDX models of pancreatic cancer [79].  A series of xenografts were established in 
 75 
nude mice by implanting surgically resected human pancreatic cancer tissue.  Mice 
were treated with EGFR inhibitor erlotinib, mTOR inhibitor temsirolimus, or vehicle 
control.  Tumor cells were sampled by fine-needle aspiration biopsy before (baseline, 
day 0) and at the completion of 28 days of treatment.  Cells obtained at baseline were 
exposed to erlotinib or temsirolimus in short-term ex vivo cell culture conditions.  
Western blot analysis was done to determine the degree of inhibition in the 
phosphorylation of extracellular signal-regulated kinase and S6-ribosomal protein.  Five 
of six xenograft tumors responded to temsirolimus, whereas only one tumor responded 
to Erlotinib (Figure 21) [79].  Erlotinib treatment failed to inhibit ERK1/2 phosphorylation 
in cells obtained from the resistant tumor A265.  The results of the ex vivo studies 
correctly predicted the pharmacodynamic effect of the agents in vivo as well as their 
gross antitumor effects.  Finally, we showed the clinical feasibility of this approach, 
performing ex vivo assessment of drug target response in FNAB samples from three 
patients with pancreatic cancer.  These effects correlated with antitumor activity in vivo.  
This previous work may provide an important tool applicable to clinical trials.  Ultimately, 
an approach of this nature may facilitate the further refinement of patient selection in 
favor of individuals with molecular profiles, predicting a greater likelihood of therapeutic 
benefit. 
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Figure 21.  Representative tumor growth and ex vivo assay data from an erlotinib-susceptible (A198) and 
an erlotinib-resistant (A265) pancreatic cancer xenograft. 
Tumor cells were obtained by FNAB before systemic treatment. Treatment with 5 µmol/L erlotinib ex vivo 
inhibited phosphorylated (P-ERK) ERK1/2 in the tumor cells obtained by FNAB from the susceptible 
tumor (A198), but not from the resistant tumor (A265). No changes were observed in total (T-ERK) levels 
of ERK1/2 in cells treated ex vivo [79]. 
 
Drug Model Erlotinib Tested on Device 
Lung adenocarcinoma xenograft mouse models produced in the lab containing 
the KRAS c.34G>T (G12C) mutation and a separate model containing the wild type (wt) 
for EGFR, were used to test the efficacy of erlotinib against negative control and 
positive control, SSP treatment groups.  Erlotinib and SSP were diluted in RPMI media 
as previously described in Chapter 3 and injected into the platform system for final 
concentrations of 1 µM and 50 µM respectively.  Two experimental groups, KRAS 
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c.34G>T (G12C) positive mutation from a mouse xenograft model and a EGFR  wt 
mouse xenograft model were tested alongside a negative vehicle control group; media 
only with 0.1% DMSO, and a 50 µM SSP positive control group and 1 µM Erlotinib 
treatment group.  FNAB tumor samples were tested at minimum in triplicate for each 
treatment group.  Availability of mouse models allowed us to test the wt EGFR group 
twice and the KRAS mutation group three times.  Some samples from each group were 
lost from analysis due to device operation failure and resulting in an unmatched number 
of samples in testing groups.  A total of 18 samples were tested in the wt EGFR group 
and a total of 27 samples were tested in the KRAS mutation group.  Each reservoir 
contained a volume of 1.5 mL singularly containing each test condition and was 
discretely circulated through each channel of the device containing a single FNAB tumor 
~300 µm fragment for a treatment period of 5 days. 
The FNAB tumor samples taken from xenograft mice were injected into each 
channel of a device and perfused with RPMI media with CalceinAM viability dye and 
apoptotic CF594-AnnexinV antibody dye, as previously described in Chapter 3.  WE 
sample was evaluated for baseline health over the course of a 12-hour period to assess 
for viability and apoptosis prior to start of each experiment.  After the 12-hour viability 
assessment, samples with a Vi ratio >0.9 were then exposed to their assigned 
experimental condition.  Images were taken of each FNAB tumor fragment for every 24-
hour time point over the course of 5 days.  The images were later analyzed for the 
tRFUs of CalceinAM and CF594-AnnexinV.  A viability index (Vi) was calculated for 
each sample at every time point and then averaged across all samples within a group 
for each time point.  Each group was evaluated by an ANOVA analysis without repeated 
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measures for each day tested across each drug condition.  Results of the ANOVA 
analysis showed a significant difference between groups for day 3 and day 4 with p < 
0.001 and a significant difference between groups at day 5 with a p < 0.005. 
Results showed a significant difference between the wt group and the KRAS 
mutation group in their response to erlotinib (Figure 22).  As demonstrated in clinic and 
mouse model, the wt group had some response to the drug although the known 
mechanism is not studied.  Importantly, the KRAS mutation model was not susceptible 
to Erlotinib.  The mechanism of action for erlotinib, as previously discussed, is not 
effective on the KRAS c.34G>T (G12C) mutation due to its downstream mutation from 
the EGFR receptor and the site of which the drug binds (Figure 23) [80].  Our results 
further validate that the system mimics the response to targeted drugs such as erlotinib 
and demonstrates the device platform’s ability to be used a predictor for how patients 
may respond in the future to drug trials. 
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Figure 22.  KRAS and wt group results from the Erlotinib validation test on device. 
wt group had a significant difference in the response to Erlotinib compared to negative control group 
similar to the positive control group (50 uM Staurosporine ) The KRAS group had a significant difference 
in the response to Erlotinib compared to the positive group (50 uM Staurosporine ) testing similar to the 
negative control group. 
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Figure 23.  Molecular mechanisms of primary and secondary resistance to anti-EGFR therapies in 
mCRC. 
The genetic mechanisms responsible for de novo and acquired resistance largely overlap. With the 
exception of EGFR mutations, which were described only in the acquired setting, all of the genetic 
alterations defined as a mechanism of de novo resistance are also responsible for acquired resistance. 
Differences can be found in the frequency of individual genetic alterations, such as KRAS and NRAS 
exon 3 mutations, which occur more frequently in the acquired rather than in the de novo setting. Text in 
red highlights the most frequent mutations. [80]. 
 
Conclusion 
Herein this chapter, we moved the testing from verifying performance of the 
device to validating clinically relevant drug models tested in clinic and alongside mouse 
models.  We gathered data previously tested with MK-1775 and gemcitabine PDX 
models and used it to compare the platforms performance to test FNAB samples 
exposed to drug using fluorescent microscopic evaluation of live/dead dyes.  Results on 
device were similar to results for mouse model.  Combinatory treatment group of 
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gemcitabine and MK-1775 showed 50-60% death and the tested MK-1775 group 
showed the most death of 70-90% compared to vehicle control group.  Gemcitabine had 
similar results to the negative control group with 10-20% cell death.  It was believed that 
the mode of interaction of the drug required a testing period longer than 48 hours.  
Secondly, the LDH results showed a similar trend with the MK-1775 group and 
combinatory group having an increase in LDH concentrations in their cultured media 
compared to the negative control and gemcitabine treatment groups, although 
gemcitabine alone did have a slight increase of LDH compared to negative control.  
Lastly, we were able to conclude that the resulting cellular death correlated with the 
metabolism of gemcitabine, dFdCTP; the active metabolized form of the drug.  
Gemcitabine challenged samples were tested by LC-MS and revealed distinct repeated 
profiles of the metabolite being present in all tested samples.  When MK-1775 samples 
were tested, we detected an unknown reproducible molecular weight signature similar 
to the MK-1775 profile compared to standard.   
The device platform was then validated a second time using a known targeted 
drug sensitive to the EGFR mutation, erlotinib.  Lung adenocarcinomas with the KRAS 
mutation are resistant to erlotinib’s mechanism of action due to the mutation being 
downstream of the binding site of the drug for the EGFR receptor.  Results showed that 
the KRAS c.34G>T (G12C) mutation responded similarly to the negative control group 
exemplifying its resistance to erlotinib.  These results show promise that the device 
platform does not incur stress to the FNAB samples and could serve as a lower profile, 
cheaper platform for chemosensitivity testing in the future.  The next step in our analysis 
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was to test the platform’s ability to recirculate T cells paired with FNAB samples 
challenged with checkpoint immune blockers, anti-PD-1 and anti-PD-L1. 
  
 83 
 
 
 
CHAPTER 5: 
IMMUNOMODUALTORY THERAPY MODELS 
 
Note to Reader 
Figures in this chapter have been previously published in Immunity, 2013, 39(1): 
doi10.1016/j.immuni.2013.07.012 [105], and have been reproduced with permission 
from the American Association of Cancer Research.  The letter of permission to reprint 
is listed in Appendix A. 
Figures in this chapter have been previously published in Trends in Molecular 
Medicine, 2013, 21(1): doi10.1016/j.molmed.2014.10.009 [106], and have been 
reproduced with permission from the American Association of Cancer Research.  The 
letter of permission to reprint is listed in Appendix A. 
 
Chapter Synopsis 
Herein we discuss the development of immunotherapies and their intended 
targets within the immune system.  The immune system is a complex interaction of cells 
that rely on the relay system of information and signals for its maturation and instruction 
to keep balance between destroying invaders foreign to the body and protecting the 
body from the over expression of those factors and killing mechanisms in protecting 
“self”.  The immune system makes up part of the microenvironment of the tumor and 
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those same cells sent to keep invaders out fail to kill tumor cells when they invade the 
body.  Tumor cells have developed functional mutations that allow them to persist and 
proliferate in conditions that normal cells would not.  Specifically, tumor cells have 
developed mechanisms of upregulation and downregulation of protein expression to 
suppress the immune system and these mechanisms, by which the tumor suppresses 
the immune system, are unique for each tumor and each patient.  Success has been 
met with the development of immunotherapy drugs that target and abrogate the 
suppressive mechanisms employed the tumor cells.  Also, immunotherapies have 
tested safer for patients with less toxic side effects than traditional chemotherapies.  In 
this chapter, we test two immunotherapy drugs, anti-PD-1 and anti-PD-L1, and evaluate 
the platform for its ability to maintain circulating T cell concentrations while tracking 
those T cells and measuring for their viability in conjunction with testing tumor models 
for targeted results. 
 
Immunology of the Tumor Microenvironment  
Although there has been tremendous advances in understanding the molecular 
and cellular biology of cancer over the past few decades, anti-cancer drug development 
has still suffered a high drug attrition rate with almost 95% of agents that demonstrated 
preclinical activity failing to demonstrate sufficient clinical safety and efficacy.  A critical 
reason for such a high failure rate is suboptimal preclinical strategies due to current 
limitations of in vitro and in vivo models to evaluate novel agents [107].  
Cancer is a complex disease involving more than just cancer cells.  A diverse 
cast of components in the surrounding microenvironment interacts with cancer cells and 
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actively facilitates malignant progression as a three-dimensional structure [108].  Two-
dimensional in vitro cultures do not reflect the complex heterogeneity of human tumor 
tissue therefore lacking the ability to predict clinical efficacy of new drugs.  Recently, 
efforts to utilize three-dimensional in vitro cancer models to investigate tumor biology 
have been increasing.  These three-dimensional cancer models include ex vivo culture 
of primary human tumor tissues or growing cancer cells in three-dimensional matrix.  Ex 
vivo culture retains the native architecture and cell heterogeneity of the tumor 
microenvironment, while cancer cells grown in three-dimensional architectures have 
been demonstrated to recapitulate somatic copy number and mutation spectra found in 
patients [109].  Both approaches represent a more rigorous model over traditional two-
dimensional culture systems and provide distinct advantages in understanding the 
translation of preclinical therapeutic efficacy to the clinic. 
The immunological component of the tumor microenvironment is complex with 
cells working either in synergy or antagonistically.  Within the tumor microenvironment, 
immune cells predominantly are CD4+ and CD8+ T cells, dendritic cells (DCs), 
macrophages and regulatory T cells (Tregs).  The quantity and quality of these immune 
cells determines the mechanism of immune response and whether the tumor may 
evade such a response through immune suppression.  Mechanisms by which the tumor 
suppresses the immune system is unique for each tumor.  The major effector cells for 
tumor elimination or killing are tumor antigen-specific CD8+ circulating t-lymphocytes 
(CTLs) for cytolytic and cytokine release.  These cells use the major histocompatibility 
complex I (MHC I) presented on cells to target and kill.  Effector cells, CD4+, may also 
kill tumor cells presented indirectly by antigen presenting cells (APCs) through MHC II.  
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Helper cells, CD4+, play a critical role in the induction and maintenance of antigen-
specific CD8+ memory T cells.  Tumor cells secrete mediators for the up regulation of 
surface inhibitory molecules and the down regulation of MHC I [110].  This in turn 
suppresses tumor infiltration dendritic cell maturation and antigen presentation and 
cross presentation, suppression of T cell infiltration, suppression of effector cell 
activation and enhances T regulatory function [111].  The chronic exposure to tumor 
antigen leads to the down regulation of co-stimulatory molecules and the upregulation of 
inhibitory molecules such as PD-1, which causes T cell exhaustion with impaired 
function [112].  Within the tumor microenvironment, CD8+ memory T cells, either central 
memory T cells (TCM) or effector memory T cells (TEM), increase the upregulation of 
PD-1.  The tumor microenvironment induces up-regulation of PD1 on the T cells and 
PD-L1 on tumor cells and therefore decreases T cell infiltration.  This blocks T cell 
responses with plasmacytoid dendritic cells inducing T reg differentiation to establish a 
tolerogenic environment.  Myeloid-derived suppressor cells suppress T cell and natural 
killer cell activation through an antigen non-specific manner with NO, ROS, arginase, IL-
10 and TGFβ while inducing and expanding the proliferation of Tregs [113] .  Tumor 
stroma cells suppress T effector cell function through TGFβ secretion and recruit 
immune suppressive cells through the secretion of CCL2 and CXCL12 [114]. 
For T cells to effectively kill tumor cells, various steps are needed for antigen 
recognition, presentation and then killing.  T cells recognize and target antigen for killing 
by recognition of the MHC I on cells directly or by the help of dendritic cells (DCs) that 
bind antigen and process the antigen with presentation to effector T cells through MHC 
II by signaling of proinflammatory cytokines such as TNFα and IL-1.  T cells are then 
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activated against such antigens and homed to the tumor and infiltrate the tumor based 
on the specific recognition between the T cell receptor (TCR) and the MHC complex.  
Next, the T effector cells kill the tumor cells with the release of IFNγ and granulocytes 
(Figure 24) [105].  There are several mechanisms why a tumor may not be recognized 
by the immune system for processing and subsequent killing.  Antigens may not be 
detected, DCs and T cells may treat antigens as self rather than foreign thereby 
creating a T regulatory cell response rather than an effector response, T cells may not 
properly home to tumors, or are inhibited from infiltrating the tumor, or factors in the 
tumor microenvironment may also suppress those effector cells that were activated 
[115].  Several successful immunotherapies have been developed to combat immune 
suppression so that the effector cells can recognize and attack tumor cells [116, 117].  
Antibody drugs that target suppressive proteins such as PD-1 and PD-L1 are proving to 
be effective in modulating how patients’ immune systems respond to their tumors.  Such 
therapies are providing compelling arguments for use beyond multiple cancer types and 
have shown promising results for a safer alternative to traditional and targeted 
therapies. 
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Figure 24.  Therapies that Might Affect the Cancer-Immunity Cycle. 
The numerous factors that come into play in the Cancer-Immunity Cycle provide a wide range of potential 
therapeutic targets. This figure highlights examples of some of the therapies currently under preclinical or 
clinical evaluation. Key highlights include that vaccines can primarily promote cycle step 2, anti-CTLA4 
can primarily promote cycle step 3, and anti-PD-L1 or anti-PD-1 antibodies can primarily promote cycle 
step 7. Although not developed as immunotherapies, chemotherapy, radiation therapy, and targeted 
therapies can primarily promote cycle step 1, and inhibitors of VEGF can potentially promote T cell 
infiltration into tumors—cycle step 5. Abbreviations are as follows: GM-CSF, granulocyte macrophage 
colony-stimulating factor; CARs, chimeric antigen receptors [105]. 
 
Anti-PD-1 and anti-PD-L1 Therapies 
In the past few years, we have seen improvements in patient outcomes resulting 
from deployment of targeted agents in subtypes of lung cancers with activating 
mutations in genes such as receptor tyrosine kinases.  However, even patients with 
activating oncogene mutations typically have limited responses to targeted agents due 
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to activation of compensatory pathways that mediate innate drug resistance to these 
targeted agents.  Epigenetics, a mechanism for switching genes on and off, such as 
errors in silencing genes for tumor suppression and DNA repair and activation of 
oncogenes by altered CpG island methylation patterns, histone modifications, and 
dysregulation of DNA binding proteins; further complicates the predictability of patient 
response to treatment.  There are epigenetic changes found in more than 70% of 
stomach and esophageal cancers and 60% of glioblastomas [118].  On average, a 
particular cancer drug is ineffective for 75% of patients [4].  Therefore, cancer cells that 
have reduced or no dependence on the therapeutic target will most often emerge or 
evolve with ultimate progression of the disease [119].  Cancer immunotherapy offers an 
attractive alternative for in turn it can aid the highly adaptable host immune response to 
recognize and kill cancer cells priming the body for a lasting durable response.  For the 
host immune response to effectively recognize and kill cancers cells, T cells; specifically 
CD8+ T cells, must first be able to recognize cancerous cells as foreign.  This 
recognition is often masked by an inhibitory signal made up of a protein ligand, 
programmed death-ligand 1 (PD-L1), that resides on the tumor cells and it’s receptor 
pair, programmed death receptor-1 (PD-1), on T cells.  When tumors express PD-L1 it 
renders the T cells inactivated by delivering an inhibitory signal reducing cytokine 
production and proliferation of the T cells and therefore evading the host immune 
response.  PD-L1 is expressed on T and B cells, dendritic cells and macrophages but 
most importantly, it is highly expressed in many human cancers.  Expression of PD-L1 
is upregulated by the expression of INFγ by T cells and also the phosphoinositide 3-
kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways [120-122]. 
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Immunotherapies such as the humanized monoclonal immunoglobulin (Ig) G4 
antibody directed against human cell surface receptor PD-1 are highly selective and are 
designed to restore the natural ability of activated T cells to recognize and target cancer 
cells by blocking the PD-1 protein from binding PD-L1 and PD-L2 which is primarily 
expressed on antigen presenting cells.  Blocking PD-1 releases a brake on the immune 
checkpoint system and inhibitory mechanisms of tumor cells against the immune 
system.  Antibodies that target PD-L1 also inhibit the binding of PD-L1 to the PD-1 
receptor such as the anti-PD-1 therapies but is rather an indirect mechanism of action 
compared to the mechanism of action of anti-PD-1 drugs (Figure 25) [106].  One 
drawback in the use of anti-PD-L1 is that high levels may be required to optimally target 
PD-L1 saturation on tumors [123].  Alternatively, anti-PD-L1 is does not target PD-L2 
and therefore is less likely to activate the TH2 response and resulting inflammation side-
effects in patients with increased levels of IL-4 [124]. 
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Figure 25.  Human cancer immunotherapy with anti-programmed death 1 (PD-1) receptor and anti-
programmed death ligand 1 (PD-L1)/L2 antibodies.  
Antigen-presenting cells (APCs) take up antigen (Ag) released from cancer cells and present it to T cells. 
Cancer cells can also present Ag to activated T cells in the context of the MHC. On T cell activation, PD-1 
receptors are expressed on T cells and inhibit immune responses by engagement of PD-L1 and PD-L2 on 
APCs and PD-L1 on cancer cells. Therefore, monoclonal antibody (mAb)-mediated specific blockade of 
the PD-1/PD-L1/PD-L2 pathway can enhance antitumor immunity. In addition to binding to PD-1, PD-L1 
and PD-L2 also bind B7-1 and repulsive guidance molecule B, respectively. In addition to T cells and 
APCs, PD-1 and PD-L1 can be induced on other immune cells [106]. 
 
Immune Therapy Model Tested on Device 
Immunotherapy is a promising new approach to cancer therapy.  It is our aim to 
demonstrate that the platform device has the novelty to model such therapies by 
mimicking the dynamic process of T cell infiltration into tumor while challenging the 
system with immunotherapies in order to characterize the microenvironment and identify 
key immune-modulators.  Furthermore, we have developed novel preclinical platforms 
to assess therapeutic potential of immunotherapy in orthotopic patient-derived xenograft 
mouse models by exposing propagated tumor infiltrating lymphocytes to autologous 
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fresh tumor tissue ex vivo and in vivo to determine their activation and cytotoxic 
efficacy. 
 
Patient-Derived Orthotopic Models 
This study was approved by the University of South Florida’s Institutional Animal 
Care and Use Committee (IACUC) and Institutional Review Board. All animals were 
maintained and evaluated in accordance with IACUC standards care in pathogen-free 
rooms at the H. Lee Moffitt Cancer Center (Tampa, FL).  Fresh tumor tissue obtained 
from patients; osteosarcoma, lung adenocarcinoma and angiosarcoma, were 
orthotopically implanted into NOD-SCID mice while the other half of the tumor was used 
for propagation of tumor infiltrating lymphocytes (TILs).  At the end of the experiment 
protocol, the animals were sacrificed by cervical dislocation after carbon dioxide 
sedation. 
 
Culturing Tumor-Infiltrating Lymphocytes 
Tumor-infiltrating lymphocytes (TILs) were cultured from small fragments 
(approximately 2mm X 2mm) of resected tumor in RPMI-1640 media containing 10% 
human AB serum, HEPES, Pen/Strep, Gentamicin, β-mercaptoethanol and 6000 IU 
rhIL-2/mL.  Each fragment was cultured in 2mL TIL media in a well of a 24 well plate 
until the TILs reach approximately 80% confluence when 50% were transferred to 
another well.  TILs were then frozen (90% hAB serum/10% DMSO) or rapidly expanded 
(30ng/mL activating anti-CD3 antibody) when there were approximately 5x107 TILs 
from a fragment.  TILs were analyzed on a BD FacsCalibur or BD LSRII flow cytometer 
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by gating on CD3+ cells and further classified the cells as CD4+ (T helper) or CD8+ 
(cytolytic) T cells on a BD FacsCalibur or BD LSRII. 
 
Analysis of TILs and Tumor on Device 
TILs were tested for an optimal concentration to be used on device and also 
tested for their ability to sustain viability over a 5-day evaluation period.  TILs were 
stained with CalceinAM before loading on device.  Also, if the test sample containing 
tumor and TILs was challenged with anti-PD-1, TILs were incubated with anti-PD-1 prior 
to loading on device.  Concentrations of 3x105, 1 x105 and 5x104 TILs/mL were tested.  
TILs were tested alone and in channel with lung adenocarcinoma FNAB.  It was found 
that 1x105 TILs/mL worked best within the system as concentrations higher than 1x105 
produced clumping within the system around the tumor clogging the channel and 
preventing flow.  Concentrations less than 1x105 challenged our abilities to collect and 
sort the TILs post experiment by flow cytometry.  Secondly, the TILs had a sustained 
viability of roughly 70% after 5 days of testing.  Viability was tested by counting the 
number of cells in each frame of a 1-minute period recorded on the microscope.  This 
was calculated and compared across each day of the experiment to determine the 
representative concentration of TILs in circulation in the system. 
Next, we wanted to test the interaction of tumor on device with autologous 
circulating TILs versus a non-matching HLA profile model.  We tested angiosarcoma 
FNAB samples either with their autologous TILs grown ex vivo or with TILs from another 
patient sample with non-matching HLA profile.  We suspected that non-autologous TILs 
would infiltrate and bind tumor more than TILs from the autologous model.  Results 
indicated no significant difference in TIL infiltration between all samples with less than 
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20% of the tumor having TILs.  Next, we tested a model of anti-PD-1 and anti-PD-L1 
immunotherapies.  Osteosarcoma and lung adenocarcinoma PDX models were chosen 
for FNAB samples for the device and were tested with either control IL-2 and anti-PD-1 
or anti-PD-L1 drug.  All TILs were activated with CD-3 prior to the experiment and 
labeled with CalceinAM green.  FNAB samples were loaded on device and perfused 
with CalceinAM blue viability stains (Molecular Probes) and CF594-Annexin V (Biotium) 
antibody added to cell culture media with binding buffer for final concentrations of 5 µM 
for each stain.  The stain solution was then used to perfuse FNAB tumor samples to 
assess for viability and apoptosis in real-time continuously over the time course of 
experiments.  Fluorescent imaging was performed by a Zeiss Axio 
ObserverZ.1/ApoTome.2 inverted scope using a 49 DAPI filter (excitation: 365 BS FT 
395/emission BP: 445/50), 378HE Green Fluorescent Protein (GFP) filter (excitation: 
450-490nm /emission: 500-550nm) and a 45 Texas Red (TR) filter (emission: 540-
580/excitation: 593-668nm) for Calcein AM and CF594-AnnexinV respectively.  ZEN 
2012 software was used to calculate the sum of intensity units throughout the FNAB 
tumor fragments in each device channel.  Background and or auto-fluorescence were 
subtracted out from each summed value of intensity.  Results showed little significance 
between the IL-2 control of the osteosarcoma FNAB sample and the drug treated anti-
PD-1 and anti-PD-L1 samples with some TIL infiltration.  The lung adenocarcinoma 
model, however, showed a differing degree of TIL infiltration and unexpectedly, we 
captured cellular death positively associated with the TIL infiltration.  The IL-2 control 
sample showed little TIL infiltration with most of the tumor still viable by the end of the 5-
day testing period.  The anti-PD-1 tested sample showed the highest degree of TIL 
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infiltration and also the most apoptosis.  The anti-PD-L1 tested sample also showed 
greater TIL infiltration compared to control but less than the anti-PD-1 treated sample 
and also less apoptosis than the anti-PD-1 sample (figures 26 and 27).  More analysis 
and a greater population of samples within each group needed to be performed to 
determine significant results. 
 
 
Figure 26.  Fluorescent image of live-dead stains of TILs in lung adenocarcinoma FNAB samples. 
IL-2 control shows little TIL infiltration (green) and viable tumor tissue (blue).  Anti-PD-1 treated FNAB has 
most TIL infiltration (green) with least viable tumor tissue (blue).  Anti-PD-L1 has moderate TIL infiltration 
(green) and cellular tumor death (blue). 
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Figure 27.  Graph of the relative fluorescent units of Live-Dead stains of TILs in lung adenocarcinoma. 
IL-2 control shows little TIL infiltration (green) and viable tumor tissue (blue).  Anti-PD-1 treated FNAB has 
most TIL infiltration (green) with least viable tumor tissue (blue).  Anti-PD-L1 has moderate TIL infiltration 
(green) and cellular tumor death (blue). 
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CONCLUSION 
Herein we described how the development of immunotherapies have 
successfully armed clinicians with an alternative to how they are treating cancer.  
Naturally, the immune system would have the means to process, detect and kill cells 
that were outgrowths or invaders of our bodies but tumors have evolved to mask 
themselves as invaders by a host of mechanisms that suppress the immune system 
from either recognizing it as foreign or deactivating the cells in charge of destroying it.  
Research into those mechanisms of evasion led researchers to develop novel drugs 
that can target those mechanisms of evasion so that the immune system can be 
activated to recognize and destroy tumor cells.  In this study we chose to test immune 
checkpoint antibody drugs targeted to the PD-1 and PD-L1 proteins to model the effects 
of the drugs on FNAB samples taken from PDX models of sarcoma, angiosarcoma and 
lung adenocarcinoma patients.  We tested limits of the device to intake T cells and 
circulate and track those cells in the system while maintaining their viability through the 
course of a 5-day evaluation of FNAB samples on device.  We also then challenged the 
model to monitor T cell infiltration into FNAB samples with and without drug.  We have 
demonstrated that the platform device has the novelty to model such therapies by 
mimicking the dynamic process of T cell infiltration into tumor while challenging the 
system with immunotherapies in order to characterize the microenvironment.  The 
platform has the ability to sustain FNAB sample on device but now, as demonstrated, 
has the ability to dynamically flow immune cells to characterize T cell infiltration and the 
killing mechanism for the evaluation of immunotherapy drugs. 
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CHAPTER SIX: 
CONCLUSION 
 
Summary of Experiments 
The aim of this work was to demonstrate that an engineered microfluidic device 
with the ability to trap FNAB tumor samples within a specifically spaced configuration of 
posts had the potential to maintain the viability of the tumor sample while supporting the 
integrity of the tumor microenvironment and thus support a more relevant and accurate 
assessment of drug response.  The long-term goal is to use the device for personalized 
cancer therapy to determine the most effective drug and drug combinations for each 
patient. 
First, we validated the design of the tumor trap device with a multi-physics model 
of fluid flow by quantitatively measuring the velocity within the channel of the device.  
We used this data to extrapolate the shear stress on the FNAB tumor fragments in trap 
and concluded that with a flow rate of 125 µL/hr, tumor fragments that occluded less 
than 70% of the channel width experienced an average shear stress less than 0.4 
dynes/cm2; a shear stress below the physiological critical threshold of 0.4 dynes/cm2 
[45, 64], with the largest shear stress located on the posts.  Next, we determined that 
the FNAB tumor fragments in trap experience full interstitial flow and therefore full drug 
perfusion demonstrated by the even distribution and uptake of the drug, doxorubicin 
HCl, throughout the entire FNAB tumor fragment in channel.  Additional findings further 
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demonstrated even drug exposure upon delivery throughout the FNAB tumor fragments 
indicated by similar temporal activities such as nuclear fragmentation and the 
production of apoptotic bodies, indicative of apoptosis occurring throughout all areas of 
the sample.  When we tested a larger protein molecule antibody for full FNAB perfusion, 
results were similar in showing penetration of the antibodies throughout the FNAB tumor 
fragments without nonspecific binding seen throughout the z-axis images.  These 
findings are important for the indication of the microfluidic system having the diverse 
capability to evaluate for large molecule antibody based targeted therapies.  Herein, we 
demonstrated a cytotoxic drug model using a known protein kinase C inhibitor, 
staurosporine [48], to optimize the microfluidic device towards a potential clinically 
relevant chemosensitivity assay.  All FNAB tumor samples were assessed for their 
viability at the onset of each experiment before randomly assigned to a treatment group.  
With the onset of the 5-day experiment, samples with a baseline Vi < 0.9 were deemed 
necrotic or nonviable and were rejected from the experiment.  For days 1 through 5, 
there was a significant difference in the viability over death between the non-treated and 
treated groups.  Although, each FNAB tumor fragment showed slight variability within 
groups in how they responded to treatment over the course of 5 days, there was a 
significant difference with the change of viability and death over the course of 5 days for 
each FNAB tumor sample between the non-treated and treated groups.  With the ability 
to evaluate viability and death in real-time, our platform affords the user to assess FNAB 
tumor samples at the onset of treatment and to evaluate its response to drug treatment 
overtime.  Real-time monitoring of treatment is a powerful tool especially for drugs that 
may be cytostatic or when in combinatorial treatment with cell cycle inhibitors.  Further, 
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the platform presents the ability for users to assess different areas of the FNAB tumor 
sample and with coordinating protein markers such as EpCAM and CD44 to know which 
cells are undergoing cell death or continued viability and evasion of drug response. 
Next, we chose chemotherapy models to validate the platform system.  We 
moved the testing from verifying performance of the device to validating clinically 
relevant drug models tested in clinic and alongside mouse models.  Choosing the right 
model implied being cognoscente of variable levels of response based on the genetic 
makeup of tumor cells from which the samples were harvested and knowing how each 
sample responded to treatment both in the clinic and in mouse.  History of drug 
response was very important in defining the parameters of testing outcomes on device.  
We chose targeted drugs, MK-1775; a Wee1 inhibitor, and Erlotinib; protein kinase 
inhibitor for EGFR associated tyrosine kinase, so that we could verify the tumor samples 
contained the protein markers targeted by the mechanism of the drugs.  Results from 
previous data tested on mouse model were used to compare the platforms performance 
to test the same model using fluorescent microscopic evaluation of live/dead dyes.  
Results on device were similar to results seen in lab and in mouse model for 
combinatory treatment group of gemcitabine and MK-1775.  Combinatory treatments 
resulted in 50-60% death and MK-1775 treatment alone group having the most death of 
70-90% compared to vehicle control group.  With gemcitabine showing similar results to 
the negative control group of 10-20% cell death, it was believed that the mode of 
interaction of the drug required a testing period loner than 48 hours for apoptotic events.  
Secondly, the LDH results showed a similar trend with the MK-1775 group and 
combinatory group having an increase of LDH compared to the negative control group.  
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Lastly, we were able to conclude that the resulting cellular death correlated with the 
metabolism of gemcitabine, dFdCTP; the active metabolized form of the drug.  Cell 
cultured media from FNAB samples tested with gemcitabine and MK-1775 revealed 
distinct repeated profiles of the metabolite being present in all tested samples when 
analyzed by LC-MS.  When MK-1775 samples were analyzed, we detected an unknown 
reproducible molecular weight signature similar to MK-1775 profile compared to 
standard. 
The device platform was then validated a second time using a known targeted 
drug sensitive to the EGFR mutation, erlotinib.  Lung adenocarcinomas with the KRAS 
mutation are resistant to the mechanism of action of erlotinib due to the mutation being 
downstream of the binding site of the drug to the EGFR receptor.  Results showed that 
the KRAS c.34G>T (G12C) mutation responded similarly to the negative control group 
exemplifying its resistance to erlotinib.  These results show promise that the device 
platform does not incur stress to the FNAB samples and could serve as a lower profile, 
cheaper platform for chemosensitivity testing in the future. 
Next, we tested the platform for handling immunomodulatory therapies to include 
recirculating T cells paired with checkpoint immune blockers, anti-PD-1 and anti-PD-L1.  
We wanted to evaluate the platform for its ability to maintain circulating T cell 
concentrations within the system with the ability to track their viability while testing 
FNAB samples with drug.  FNAB samples were taken from PDX models of sarcoma, 
angiosarcoma and adenocarcinoma patients.  We tested limits of the device to intake T 
cells and circulate and track those cells in the system during a 5-day evaluation of 
FNAB samples on device.  We also then challenged the model to monitor T cell 
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infiltration into FNAB samples with and without drug.  Results showed similar to clinic 
with increased T cell infiltration into FNAB sample when anti-PD-1 and anti-PD-L1 were 
used and an increase of associated apoptosis of tumor cells.  We demonstrated that the 
platform device has the novelty to model such therapies by mimicking the dynamic 
process of T cell infiltration into tumor while challenging the system with 
immunotherapies in order to characterize the microenvironment.  The platform was 
shown to have the ability to sustain FNAB sample on device but now, as demonstrated, 
also has the ability to dynamically characterize T cell infiltration for the evaluation of 
immunotherapy drugs. 
 
The clinical process of deciding a chemotherapy regime is based on empirical 
information from clinical trials of patients which ignores biological individuality of the 
tumor [125].  Patient-to-patient response is variable with anti-cancer drugs showing a 
high degree of variation due to each individual patient's tumor being genotypically and 
phenotypically different [126].  For treatment regimens to be more effective and 
personalized to each patient, chemosensitivity assays need to be tailored to evaluate 
the patient's cancer and how it responds to chemotherapy.  Personalized information 
can better assist doctors to select effective chemotherapy regimens for individual 
patients.  Various chemosensitivity assays used in clinic have been comprehensively 
reviewed [6, 7] but inadequately developed to recapitulate in vivo like conditions.  
Current chemosensitivity assays test an isolated subset of cells expanded from a tumor 
biopsy and cultured as a monolayer on a well plate.  To accurately assess the efficacy 
of chemotherapy among patients, a physiologically meaningful model should be used 
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that incorporates not only the cancer cells but also its microenvironment with its 
supporting stromal components.  The platform must be stable and with the culture 
environment well-defined.  Such chemosensitivity assays utilize cells cultured as a 
monolayer in two-dimensional models that lack the true representation of the three-
dimensional microenvironment and cell to cell interactions seen in vivo.  Cancer cells 
grown in three-dimensional environments often show more resistance to cytotoxic 
agents than those grown in two-dimensional cultures [18].  Formation of polarized, 
three-dimensional structures confers protection to cell death where in contrast, 
nonpolarized structures are sensitive to induction of apoptosis.  Weaver et al. found that 
epithelial tumors that express 4-integrins have the potential to acquire resistance to 
exogenous death stimuli if they are given the appropriate spatial and biochemical cues 
from the microenvironment.  Therefore, regardless of the genetic makeup, the rate of 
growth, or the malignant status, resistance correlates with ECM composition, 
hemidesmosome-dependent polarity, and nuclear factor kappa B activation [16].  A 
further drawback with in vitro chemosensitivity assays are the poorly defined culture 
conditions caused by chemical gradients in conventional static cell culture formats such 
as the well plate.  In static well plate cell culture, support media is manually introduced 
or replaced periodically in a batch-wise manner.  Such a nonhomogeneous and 
fluctuating culture environment may complicate the investigation and quantification of a 
cellular response to drug conditions as cellular physiology is fairly sensitive to the 
extracellular conditions [28].  A cell culture system using continuous fluid perfusion 
provides circulation of nutrients and waste maintaining a stable homogeneous culturing 
environment [8, 127].  Secondly, three-dimensional models do not have a 
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homogeneous microenvironment and therefore, culturing cells in three dimensions 
crucially perturbs the way the cells respond to chemotherapeutic agents [128].  In cases 
where the three-dimensional tissue’s radius exceeds 400 µm, concentration gradients 
are evident where the available oxygen, metabolites, or therapeutic agents form inward 
gradients while that of carbon dioxide or excreted cell waste, or the acidity of 
extracellular fluid form outward gradients [129-131].  These gradients, and the 
downstream consequences that follow them, form the basis for the increased drug 
resistance that may be observed specifically in three-dimensional system[132].  
Importantly, such gradients do exist within in vivo tumor tissues, and they interfere with 
the efficacy of a chemotherapeutic treatment [132].  Additionally, cells in a two-
dimensional model often experience shear stress that are non-physiological and are 
harmful for cell viability.  Chang et al. found that incubation under static conditions for 24 
or 48 hours led to G0/G1 arrest; in contrast, shear stress (12 dynes/cm2) induced G2/M 
arrest [44].  Specifically, induced shear stress increased expressions of cyclin B1 and 
p21CIP1 and decreased expressions of cyclins A, D1, and E, cyclin-dependent protein 
kinases (Cdk)-1, -2, -4, and -6, and p27KIP1 as well as a decrease in Cdk1 activity.  
Also, shear-induced sensitization directly correlates with the application of fluid shear 
stress, and TRAIL-induced apoptosis increases in a fluid shear stress force- and time-
dependent manner that is caspase dependent [64].  Therefore, to accurately assess the 
efficacy of chemotherapy among patients, chemosensitivity assays need to be a 
physiologically meaningful model that are stable and well-defined incorporating a three-
dimensional microenvironment with its ability to foster cell-to-cell interactions that play 
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important roles to determine its cellular fate as they undergo proliferation, differentiation 
or apoptosis. 
The concept of microfluidics offers a low volume, miniaturized method for 
culturing and studying cellular and tissue concepts in a stable, well-defined, and more 
biologically relevant culture environment.  Conversely, more traditional methods of cell 
culturing such as well plate assays are relatively large in scale requiring several 
hundreds of microliters to milliliters in volume with a greater demand of reagents and 
requiring a larger sampling population cells and or tissue.  With the progress in 
microfabrication and microfluidic technology, microfluidic systems have been 
progressively used as versatile cell culture tools for various research purposes.  The 
application of microfluidic cell culture has particularly gained more interest for drug 
research.  Current studies of cancer dynamics within microfluidic systems have 
principally focused on evaluating the steps involved in cancer cell metastasis, with a 
benefit of these studies being that these factors make ideal biomarkers in many 
instances.  In such studies, tumor cells have been exposed to differing shear stresses 
and chemokine gradients, parameters that change in capillaries in vivo, to study factors 
thought to be involved in generating circulating tumor cells [133, 134].  Others have 
examined the site of attachment and adhesion itself through the use of isotropic silicon 
microstructures and matrigel lined with human microvascular endothelial cells 
highlighting the biomechanical properties of normal and cancer cells [135, 136].  A third 
group of studies have examined cell deformability, to distinguish between normal, 
benign, and metastatic cancer cells using antibody-coated microchannels, to develop a 
test for metastatic disease [137, 138].  Several of these research groups developed 
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these microfluidic devices with chambers, posts, microbubble array, or microwells to 
analyze single cell behavior or trap cells in cluster, which would eventually grow into 
spheroids.  Single cell two-dimensional models have their limitations and spheroids, 
although three-dimensional in conformation, rely on co-culturing cell lines that do not 
represent a model of personalized treatment for patients.  Hattersley et al. successfully 
demonstrated the ability to model cell death by chemotherapeutic agents in head and 
neck squamous cell carcinoma biopsies although analysis was performed offline without 
real-time microscopic evaluation of the tumor microenvironment with dependency of 
dissemination and lysis of the biopsy sample [42]. 
 Herein, we described a microfluidic platform with the ability to sustain FNAB 
tumor samples with full interstitial perfusion for the real-time monitoring of 
chemotherapy.  The trapping posts within the device were strategically engineered to be 
spaced to retain the FNAB in channel during flow and to allow interstitial flow within the 
channel fostering full fluid perfusion of the FNAB tumor fragments.  If the posts were 
spaced too wide the FNAB tumor sample would be lost in flow.  If the posts were 
spaced too close back pressure would be created with most of the fluid traveling around 
the outside of the FNAB rather than interstitially through the FNAB tumor sample.  
Results from both the fluorescent bead assay in flow and the doxorubicin HCl drug 
perfusion study indicated that the FNAB tumor fragments are in close contact with the 
fluid front on all sides of the sample.  The doxorubicin HCl drug perfusion experiment 
exemplifies advective properties with drug uptake throughout the whole sample in a 
simultaneous manner rather than as a progressive gradient in a diffusion manner with 
subsequent apoptotic events happening simultaneously throughout the entire sample.  
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Additionally, the large molecule antibody experiment demonstrated antibodies bound to 
conjugate membrane proteins throughout the interior of the FNAB tumor samples 
shown through various z-axis images.  These findings validate and further exemplify the 
advective properties of bulk fluid flow within the channel rather than dependence on 
diffusion alone.  Traps engineered in other microfluidic devices have similar orientations 
but different dimensions and spacing that do not offer full interstitial flow and therefore 
resulting in chemical gradients with unstable nonhomogeneous microenvironments.  
Khoury et al. found that embryonic stem cell aggregates can asymmetrically 
differentiate in relation to their location within the microfluidic trap, and in close 
correlation with the state of the culture medium potentiating nutrient concentration 
gradients.  Cells that were shielded from flow were exposed to lower nutrient levels and 
were most likely exposed to higher concentrations of excreted factors.  Reduced 
nutrition and serum starvation has been shown to reduce proliferation rates and hinder 
cell cycle progression [139]. 
 While two-dimensional cell culture models have their limitations, in vivo mouse 
models suffer the disadvantages of expense and the limitations of multiplexing for 
statistical relevance with unfavorable ethical concerns.  Microfluidic devices have been 
widely used for investigation of cellular responses and viability.  Microfluidic devices 
offer controlled environments for regulatory signals such as cytokines and physical 
factors like hydrodynamic shear with low burden on reagent use.  Unlike a static cell 
culture, a perfusion cell culture model can provide a system for continuous nutrient 
supply and waste removal, thereby maintaining a more stable culture environment [9, 
28].  We have created a stable and quantifiable fluid delivery system that provides 
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circulation found in the body with the relevant pressures and shear experienced by solid 
tumors in situ. 
 Herein we demonstrated a microfluidic device capable of trapping and 
maintaining the viability of FNAB tumor samples for the investigation of chemotherapy 
efficacy.  We have shown that the fluid dynamics of the device operate at values that 
are physiologically relevant without insult or harm to the sample.  Also, we 
demonstrated that the FNAB samples are fully exposed to drug infusion without the 
production of gradients so that a full and robust determination of drug effect may be 
ascertained from the viability results.  Lastly, we demonstrated the device has the ability 
to mimic results seen in clinic and mouse models when challenged with targeted and 
immunotherapy drug models.  
 
Limitations of the Tumor Trapping Device and Platform 
Within Chapter 2, we discussed the fabrication methods of the tumor trap device.  
PDMS was used as the material of choice mainly for its ease of use the fabrication 
method of soft photolithography, its optical properties, low cost and therefore 
disposable.  Although soft photolithography is a relatively easy and cheap fabrication 
process it has its own constraints for the tolerance of device features to ~100um.  In 
order to have taller features one would have to perform an additive process ensuring 
that previously deposited features aligned with newly added ones, often a non-
repeatable and strenuous process.  Other fabrication processes that allow for taller 
features include machining, injection molding and lamination which all have their own 
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limitations for tolerances and importantly, higher costs.  Unfortunately, PDMS has the 
chemical properties of being hydrophobic and therefore is limited to materials of which it 
can bond necessitating glues and or epoxies that can prove to be biologically 
incompatible and or detrimental to cell culture.  PDMS absorption has the potential to 
alter solution concentrations of cell culture components such as certain essential amino 
acids, vitamins, steroids, hormones, neurotransmitters, eicosanoids, and growth factors. 
The loss of such molecules could lead to reduced growth or alter phenotypic behavior in 
cell culture, which might then be incorrectly attributed to other factors [140].  This is 
important as the material bonds to small molecules it may elute out drug altering drug 
concentrations within device and also cytokine messengers important in drug response 
and signals for cellular behavior such as proliferation and or apoptosis.  Secondly, the 
connections of the inlet and outlets of the device are not rigid in that the PDMS flexes 
and therefore deformable negating an air tight seal and possible leaking with back 
pressure of resistive fluids.  Importantly, PDMS is gas permeable allowing the exchange 
of oxygen gas across its surface [55].  Lastly, because the material is gas permeable it 
limits the gas conditions of which user may expose the cells to.  As stated, tumors are 
normally exposed to hypoxic conditions and therefore, tumors cells respond specifically 
to those conditions with upregulation of proteins and pathway activation to thrive in such 
conditions.  It has been shown that in hypoxic conditions the H1F1 pathway and NFkB 
pathway are activated inducing upregulation of protein synthesis and selective 
differentiation of cells is regulated by dynamic changes in oxygen tension [56].  
Metabolic changes in response to hypoxia are elicited through both direct mechanisms, 
such as the reduction in ATP generation by oxidative phosphorylation or inhibition of 
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fatty-acid desaturation, and indirect mechanisms including changes in isozyme 
expression through hypoxia-responsive transcription factor activity [57].  With tumors 
growing in hypoxic conditions and adapting to these conditions it is important that we 
mimic these models with the same in vivo like conditions.  Therefore, the ability to 
control gas concentrations in culture is very useful as it ultimately affects how the 
tumors may respond to drug insult.  Using a permeable material would not allow hypoxic 
conditions to persist, as the device would necessitate a secondary enclosure hindering 
inline and real-time analysis.  One way in which we planned to overcome the limitations 
of PDMS was to design a generation 2 device that was made from COC; a hard plastic 
with optimal optical transmission properties and inert with biocompatibility and non-
absorbing.  The generation 2 device is a closed system (non gas permeable) with gas 
levels monitored by sensor and tunable to hypoxic conditions. 
In Chapter 3, we examined the flow properties of the device with tumor in trap.  It 
was found that the media perfused through the entire tumor and that small molecule 
drug and larger proteins could penetrate through the interior of the FNAB sample.  This 
is optimal when testing the effects of drug insult compared to two-dimensional well plate 
models where in 2-dimensional models the limit of diffusion is unknown and therefore 
also the degree of insult of drug.  However, there are limitations to this model.  Tumors 
in situ normally have areas of the tumor that are hypoxic and devoid of perfusion due to 
limited vasculature and lymphatic vessels penetrating into the tumor.  As the tumor 
grows a greater necrotic core becomes evident.  Because of the limits of the 
vasculature, drug penetration is also limited.  Our model does not operate to include for 
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a non-perfusion model but could be altered to meet such a specification by 
accommodating larger tumors and resistive flow.    
In Chapter 4 and 5 we sought to validate the device against drug response 
normally seen in clinic and in lab previously tested.  One such model used the 
immunotherapies anti-PD-1 and anti-PD-L1.  Normally, there are mechanisms by which 
the tumor suppresses the immune system.  Tumor cells secrete mediators for the up 
regulation of surface inhibitory molecules and the down regulation of MHC I [110].  This 
in turn suppresses tumor infiltration dendritic cell maturation and antigen presentation 
and cross presentation, suppression of T cell infiltration, suppression of effector cell 
activation and enhances T regulatory function [111].  The chronic exposure to tumor 
antigen leads to the down regulation of co-stimulatory molecules and the upregulation of 
inhibitory molecules such as PD-1, which causes T cell exhaustion with impaired 
function [112].  Within the tumor microenvironment, CD8+ memory T cells, either central 
memory T cells (TCM) or effector memory T cells (TEM), increase the upregulation of 
PD-1.  The tumor microenvironment induces up-regulation of PD1 on the T cells and 
PD-L1 on tumor cells and therefore decreases T cell infiltration.  This blocks T cell 
responses with plasmacytoid dendritic cells inducing T reg differentiation to establish a 
tolerogenic environment.  Myeloid-derived suppressor cells suppress T cell and natural 
killer cell activation through an antigen non-specific manner with NO, ROS, arginase, IL-
10 and TGFβ while inducing and expanding the proliferation of Tregs [113] .  Tumor 
stroma cells suppress T effector cell function through TGFβ secretion and recruit 
immune suppressive cells through the secretion of CCL2 and CXCL12 [114].  In testing 
an immunotherapy drug it is important to incorporate such mechanisms of inhibition.  At 
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a minimum, a relevant model would incorporate T regulatory cells.  It would track the 
differentiation of PBMCs and the 2 branches of a cytolytic response versus a cytotoxic 
response and the activation of T memory cells versus effector cells and concerted effort 
in the evasion of drug response. 
 
Future Work and Recommendations 
In future work, we plan to meet requirements that were not fulfilled in this 
generation of device work such using nonabsorbent materials to fabricate the device 
and including for hypoxic conditions that require a closed circulating system.  We also 
plan to perform larger biopsies samples of tumors to include for greater cell populations 
and therefore a more representative tumor microenvironment.  This will be done in 
incorporating a pressurized vacuum that drives the fluid from a pressurized vessel.  This 
vessel will be pressurized with a gas mixture that will include hypoxic conditions of 1-
12% oxygen monitored by sensor feedback that is tunable.  Additionally, the flow rate 
will be continuously monitored with feedback graphical user interface (GUI) software 
and command algorithms that will receive performance values and adjust pressure to 
meet input values.  With larger FNAB samples of varying size, having automated control 
will allow for monitoring shear stresses while flow rates change due to varying resulting 
resistance of fluid flow in the system.  Lastly, validation will need to be performed on 
direct patient samples for multiple treatment categories and therefore scale up of the 
number of conditions and also the number of samples on device. 
Microfluidics can be a valuable tool for cancer investigation and ultimately 
clinicians in providing insight into the best treatment options tailored to each patient.  
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The device has the potential to predict patient response before initiation of therapy that 
would help to design the most efficient therapeutic regimen for individual patients while 
sparing others who are not likely to benefit from the given therapy.  
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